---
http_interactions:
- request:
    method: post
    uri: https://sciencewirerest.discoverylogic.com/PublicationCatalog/PublicationQuery?format=xml
    body:
      encoding: UTF-8
      string: |-
        <?xml version="1.0"?>
              <ScienceWireQueryXMLParameter xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
              <xmlQuery><![CDATA[
               <query xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/
              XMLSchema">
                <Criterion ConjunctionOperator="AND">
                  <Criteria><Criterion>
                      <Filter>
                        <Column>Title</Column>
                        <Operator>Contains</Operator>
                        <Value>lung cancer treatment</Value>
                      </Filter>
                    </Criterion></Criteria>
                </Criterion>
                <Columns>
                  <SortColumn>
                    <Column>Rank</Column>
                    <Direction>Descending</Direction>
                  </SortColumn>
                </Columns>
               <MaximumRows>20</MaximumRows>
              </query>
              ]]></xmlQuery>
              </ScienceWireQueryXMLParameter>
    headers:
      Accept-Encoding:
      - gzip;q=1.0,deflate;q=0.6,identity;q=0.3
      Accept:
      - "*/*"
      User-Agent:
      - Ruby
      Licenseid:
      - Settings.SCIENCEWIRE.LICENSE_ID
      Host:
      - Settings.SCIENCEWIRE.HOST
      Connection:
      - Keep-Alive
      Expect:
      - 100-continue
      Content-Type:
      - text/xml
  response:
    status:
      code: 200
      message: OK
    headers:
      Cache-Control:
      - private
      Content-Type:
      - application/xml; charset=utf-8
      Server:
      - Microsoft-IIS/7.5
      X-Aspnetmvc-Version:
      - '2.0'
      X-Aspnet-Version:
      - 4.0.30319
      X-Powered-By:
      - ASP.NET
      Date:
      - Tue, 05 Apr 2016 23:40:16 GMT
      Content-Length:
      - '279'
    body:
      encoding: UTF-8
      string: "<?xml version=\"1.0\"?>\r\n<ScienceWireQueryIDResponse xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\"
        xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\r\n  <queryID>50106</queryID>\r\n
        \ <queryResultRows>20</queryResultRows>\r\n  <totalRows>20</totalRows>\r\n</ScienceWireQueryIDResponse>"
    http_version: 
  recorded_at: Tue, 05 Apr 2016 23:40:16 GMT
- request:
    method: get
    uri: https://sciencewirerest.discoverylogic.com/PublicationCatalog/PublicationQuery/50106?format=xml&page=0&pageSize=2147483647&v=version/3
    body:
      encoding: US-ASCII
      string: ''
    headers:
      Accept-Encoding:
      - gzip;q=1.0,deflate;q=0.6,identity;q=0.3
      Accept:
      - "*/*"
      User-Agent:
      - Ruby
      Content-Type:
      - text/xml
      Licenseid:
      - Settings.SCIENCEWIRE.LICENSE_ID
      Host:
      - Settings.SCIENCEWIRE.HOST
      Connection:
      - Keep-Alive
  response:
    status:
      code: 200
      message: OK
    headers:
      Cache-Control:
      - private
      Content-Type:
      - application/xml; charset=utf-8
      Server:
      - Microsoft-IIS/7.5
      X-Aspnetmvc-Version:
      - '2.0'
      X-Aspnet-Version:
      - 4.0.30319
      X-Powered-By:
      - ASP.NET
      Date:
      - Tue, 05 Apr 2016 23:40:16 GMT
      Content-Length:
      - '65372'
    body:
      encoding: UTF-8
      string: "<?xml version=\"1.0\"?>\r\n<ArrayOfPublicationItem xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\"
        xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75315890</PublicationItemID>\r\n    <Title>Evaluation
        of melanoma antigen gene A3 expression in drug resistance of epidermal growth
        factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung
        cancer treatment</Title>\r\n    <Abstract>Objective: To investigate the correlation
        between melanoma antigen gene A3 (MAGE-A3) expression and progression-free
        survival (PFS) of nonsmall cell lung cancer (NSCLC) patients with epidermal
        growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) therapy, aiming
        to provide a basis for research and treatment of EGFR-TKIs resistance. Research
        and Methods: Retrospective analysis is conducted of PFS of 359 NSCLC patients
        who have been tested positive for EGFR, and experienced drug resistance during
        oral treatment of icotinib. MAGE-A3 expression is tested using immunology
        and histology chemistry methods, and T790M and c-MeT expression are tested
        using mutation-enriched polymerase chain reaction. Results: (1) MAGE-A3 expression
        in targeted treatment of NSCLC patients shows a positive rate of 33.98%. The
        comparative difference between MAGE-A3 expression and T790M, c-MeT and other
        resistance genes was not statistically significant (P &gt; 0.05). (2) MAGE-A3
        expression was higher in patients with NSCLC targeted therapy of primary drug
        resistance of positive rate than acquired resistance; meanwhile the expression
        level differences in three modes of acquired resistance are statistically
        significant (P &lt; 0.05). (3) PFS of MAGE-A3 positive expression in the targeted
        treatment of acquired drug resistance in patients with NSCLC is shorter than
        the PFS of MAGE-A3 negative expression (P = 0.01); the comparative PFS differences
        in the three kinds of acquired drug resistance pattern have statistical significance
        (P = 0.02). (4) PFS and levels of MAGE-A3 expression in NSCLC patients with
        the three modes of acquired resistance are negatively correlated (P &lt; 0.01),
        and MAGE-A3 expression has no correlation with age, gender, pathological type
        or PS score (P &gt; 0.05). Conclusion: MAGE-A3 expression in EGFR-TKIs target
        therapy in NSCLC patient suggests that there might be EGFR-TKIs drug resistance,
        and the higher the level of expression, the shorter the time of acquired drug
        resistance.</Abstract>\r\n    <AuthorList>Jin,Ju,|Liu,Bang-Zhu,|Wu,Zhuo-Min,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList>CARCINOMA|DOCETAXEL|GEFITINIB|lung
        cancer|drug resistance|target therapy|Melanoma antigen gene-A3</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>9</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000370873700009</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF CANCER RESEARCH AND THERAPEUTICS</PublicationSourceTitle>\r\n
        \   <Volume>11</Volume>\r\n    <Issue>8</Issue>\r\n    <Pagination>271-274</Pagination>\r\n
        \   <PublicationDate>2015-11-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0973-1482</ISSN>\r\n    <DOI>10.4103/0973-1482.170549</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>0</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>MEDKNOW
        PUBLICATIONS &amp; MEDIA PVT LTD</CopyrightPublisher>\r\n    <CopyrightCity>MUMBAI</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>0.791,2014,ClosestToPublicationYear|0.791,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>197/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|197/211;ONCOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>INDIA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>75210085</PublicationItemID>\r\n
        \   <Title>On the pharmacogenetics of non-small cell lung cancer treatment</Title>\r\n
        \   <Abstract>Introduction. Despite many clinical efforts, non-small-cell
        lung cancer (NSCLC) has a dismal 5-year survival rate of 16%, and high incidence
        of recurrence. The success of biologically targeted agents, as well as the
        activity of well-established chemotherapeutic regimens, has been limited by
        inherited/acquired resistance, and biomarkers to adapt the prescription of
        anticancer drugs to patients' features are urgently warranted.  Areas covered.
        In oncology, pharmacogenetics should provide the way to select patients who
        may benefit from a specific therapy that best match the individual and tumor
        genetic profile, thus allowing maximum activity and minimal toxicity. The
        present review summarizes the main findings on NSCLC pharmacogenetics, critically
        reappraising the most important studies on polymorphisms correlated with outcome
        of pemetrexed and EGFR-inhibitors, and provides perspective on clinical application
        of genomic tests for treatment decision-making.  Expert Opinion. A major challenge
        in NSCLC is the identification of subgroups of diseases/patients that will
        truly benefit from specific treatments. Ideally, convenient and minimally
        invasive tests to decipher biomarkers of chemosensitivity/resistance and toxicity
        should be developed alongside novel anticancer treatments. Integration with
        the latest generation of whole-genome analyses and liquid biopsies as well
        as prospective validation in large cohorts of patients will overcome the limitations
        of the traditional pharmacogenetic approaches.</Abstract>\r\n    <AuthorList>Santarpia,Mariacarmela,|Rolfo,Christian,|Peters,G,J|Leon,Leticia,G|Giovannetti,Elisa,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList>GENOME-WIDE ASSOCIATION|PLATINUM-BASED
        CHEMOTHERAPY|MESSENGER-RNA|GROWTH-FACTOR RECEPTOR|DINUCLEOTIDE REPEAT POLYMORPHISM|THYMIDYLATE
        SYNTHASE|INTRON 1|RANDOMIZED PHASE-II|TYROSINE KINASE INHIBITORS|PEMETREXED-BASED
        CHEMOTHERAPY|lung cancer|pemetrexed|EGFR inhibitors|methodological challenges|pharmacogenetic
        studies</KeywordList>\r\n    <DocumentTypeList>Review</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>99</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26761638</PMID>\r\n    <WoSItemID>000370753000002</WoSItemID>\r\n
        \   <PublicationSourceTitle>EXPERT OPINION ON DRUG METABOLISM &amp; TOXICOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>12</Volume>\r\n    <Issue>3</Issue>\r\n    <Pagination>307-317</Pagination>\r\n
        \   <PublicationDate>2016-03-03T00:00:00</PublicationDate>\r\n    <PublicationYear>2016</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Biochemistry
        &amp; Molecular Biology|Pharmacology &amp; Pharmacy</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1742-5255</ISSN>\r\n    <DOI>10.1517/17425255.2016.1141894</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>1</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>TAYLOR
        &amp; FRANCIS LTD</CopyrightPublisher>\r\n    <CopyrightCity>ABINGDON</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.831,2014,ClosestToPublicationYear|2.831,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>94/254;PHARMACOLOGY &amp; PHARMACY;2014;SC;ClosestToPublicationYear|138/289;BIOCHEMISTRY
        &amp; MOLECULAR BIOLOGY;2014;SC;ClosestToPublicationYear|94/254;PHARMACOLOGY
        &amp; PHARMACY;2014;SC;MostRecentYear|138/289;BIOCHEMISTRY &amp; MOLECULAR
        BIOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>OXON</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75182037</PublicationItemID>\r\n    <Title>The Utilization
        of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy.</Title>\r\n
        \   <Abstract>Lung cancer is ranked first worldwide as one of the main cancers
        in terms of prevalence and mortality rate. The development of effective treatment
        strategies against lung cancer is therefore of paramount importance. Traditionally,
        chemotherapy was employed in the treatment of various cancers. However, the
        non-specific nature of the actions of chemotherapeutic drugs and the potential
        for tumors to develop resistance to these drugs may render chemotherapy a
        less favorable option for cancer treatment. Immunotherapy provides an alternative
        strategy for this purpose. It involves the utilization of the immune system
        and the immune effector cells to elicit an immune response to the tumors,
        thereby eliminating them. Strategies include the administration of pro-inflammatory
        cytokines for immune stimulation, the removal of immunological checkpoints
        using monoclonal antibodies, and the use of cancer vaccines to enhance immunity
        against tumors. This article summarizes the above strategies, highlights the
        reasons why immunotherapy is superior to chemotherapy for the purpose of tumor
        removal, and reviews the recent clinical studies comparing the clinical outcomes
        of patients undergoing immunotherapy and chemotherapy. The article also describes
        advances in immunotherapeutic strategies for the treatment of lung cancer.
        </Abstract>\r\n    <AuthorList>Chan,Carmen,WH|Tsui,Stephen,KW|Law,Bernard,MH|So,Winnie,KW|Tang,Fiona,WK|Wong,Cho-Lee,</AuthorList>\r\n
        \   <AuthorCount>6</AuthorCount>\r\n    <KeywordList>chemotherapy|immune system|immunotherapy|lung
        cancer</KeywordList>\r\n    <DocumentTypeList>Journal Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>26927069</PMID>\r\n    <PublicationSourceTitle>International
        journal of molecular sciences</PublicationSourceTitle>\r\n    <Volume>17</Volume>\r\n
        \   <Issue>3</Issue>\r\n    <PublicationDate>2016-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2016</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>1422-0067</ISSN>\r\n    <DOI>10.3390/ijms17030286</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>2</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <PublicationImpactFactorList>2.862,2014,ClosestToPublicationYear|2.862,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>134/289;BIOCHEMISTRY &amp; MOLECULAR BIOLOGY;2014;SC;ClosestToPublicationYear|45/157;CHEMISTRY,
        MULTIDISCIPLINARY;2014;SC;ClosestToPublicationYear|134/289;BIOCHEMISTRY &amp;
        MOLECULAR BIOLOGY;2014;SC;MostRecentYear|45/157;CHEMISTRY, MULTIDISCIPLINARY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>SWITZERLAND</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>74993773</PublicationItemID>\r\n
        \   <Title>Lung cancer treatment is influenced by income, education, age and
        place of residence in a country with universal health coverage</Title>\r\n
        \   <Abstract>Selection of lung cancer treatment should be based on tumour
        characteristics, physiological reserves and preferences of the patient. Our
        aims were to identify and quantify other factors associated with treatment
        received. Lung cancer patient data from 2002 to 2011 were obtained from the
        national population-based Cancer Registry of Norway, Statistics Norway and
        the Norwegian Patient Register. Multivariable logistic regression examined
        whether year of diagnosis, age, sex, education, income, health trust, smoking
        status, extent of disease, histology and comorbidities were associated with
        choice of treatment; surgery or radical or palliative radiotherapy, within
        1 year of diagnosis. Among the 24,324 lung cancer patients identified, the
        resection rate remained constant while the proportion of radical radiotherapy
        administered increased from 8.6 to 14.1%. Older patients, those with lower
        household incomes and certain health trusts were less likely to receive any
        treatment. Lower education and the male gender were identified as negative
        predictors for receiving surgery. Smoking history was positively associated
        with both radical and palliative radiotherapy, while comorbidity and symptoms
        were independently associated with receiving surgery and palliative radiotherapy.
        Although Norway is a highly egalitarian country with a free, universal healthcare
        system, this study indicates that surgery and radical and palliative radiotherapy
        were under-used among the elderly, those with a lower socioeconomic status
        and those living in certain health trusts.</Abstract>\r\n    <AuthorList>Nilssen,Yngvar,|Strand,Trond-Eirik,|Fjellbirkeland,Lars,|Bartnes,Kristian,|Brustugun,Odd,Terje|O'Connell,Dianne,L|Yu,Xue,Qin|Moller,Bjorn,</AuthorList>\r\n
        \   <AuthorCount>8</AuthorCount>\r\n    <KeywordList>SWEDEN|INEQUALITIES|SURGERY|SURGICAL
        RESECTION|SURVIVAL|NORWAY|STAGE|RADIOTHERAPY|SOCIOECONOMIC POSITION|PALLIATIVE
        RADIATION-THERAPY|surgery|lung cancer|radiotherapy|national population-based</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>36</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26421593</PMID>\r\n    <WoSItemID>000370080900005</WoSItemID>\r\n
        \   <PublicationSourceTitle>INTERNATIONAL JOURNAL OF CANCER</PublicationSourceTitle>\r\n
        \   <Volume>138</Volume>\r\n    <Issue>6</Issue>\r\n    <Pagination>1350-1360</Pagination>\r\n
        \   <PublicationDate>2016-03-15T00:00:00</PublicationDate>\r\n    <PublicationYear>2016</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0020-7136</ISSN>\r\n    <DOI>10.1002/ijc.29875</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>3</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>WILEY-BLACKWELL</CopyrightPublisher>\r\n    <CopyrightCity>HOBOKEN</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>5.085,2014,ClosestToPublicationYear|5.085,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>31/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|31/211;ONCOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NJ</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>74987116</PublicationItemID>\r\n    <Title>4D cone
        beam CT-based dose assessment for SBRT lung cancer treatment</Title>\r\n    <Abstract>The
        purpose of this research is to develop a 4DCBCT-based dose assessment method
        for calculating actual delivered dose for patients with significant respiratory
        motion or anatomical changes during the course of SBRT. To address the limitation
        of 4DCT-based dose assessment, we propose to calculate the delivered dose
        using time-varying ('fluoroscopic') 3D patient images generated from a 4DCBCT-based
        motion model. The method includes four steps: (1) before each treatment, 4DCBCT
        data is acquired with the patient in treatment position, based on which a
        patient-specific motion model is created using a principal components analysis
        algorithm. (2) During treatment, 2D time-varying kV projection images are
        continuously acquired, from which time-varying 'fluoroscopic' 3D images of
        the patient are reconstructed using the motion model. (3) Lateral truncation
        artifacts are corrected using planning 4DCT images. (4) The 3D dose distribution
        is computed for each timepoint in the set of 3D fluoroscopic images, from
        which the total effective 3D delivered dose is calculated by accumulating
        deformed dose distributions. This approach is validated using six modified
        XCAT phantoms with lung tumors and different respiratory motions derived from
        patient data. The estimated doses are compared to that calculated using ground-truth
        XCAT phantoms. For each XCAT phantom, the calculated delivered tumor dose
        values generally follow the same trend as that of the ground truth and at
        most timepoints the difference is less than 5%. For the overall delivered
        dose, the normalized error of calculated 3D dose distribution is generally
        less than 3% and the tumor D95 error is less than 1.5%. XCAT phantom studies
        indicate the potential of the proposed method to accurately estimate 3D tumor
        dose distributions for SBRT lung treatment based on 4DCBCT imaging and motion
        modeling. Further research is necessary to investigate its performance for
        clinical patient data.</Abstract>\r\n    <AuthorList>Cai,Weixing,|Dhou,Salam,|Cifter,Fulya,|Myronakis,Marios,|Hurwitz,Martina,H|Williams,Christopher,L|Berbeco,Ross,I|Seco,Joao,|Lewis,John,H</AuthorList>\r\n
        \   <AuthorCount>9</AuthorCount>\r\n    <KeywordList>IMAGE|FEASIBILITY|VERIFICATION|RESPIRATORY
        MOTION|MONTE-CARLO|STEREOTACTIC BODY RADIOTHERAPY|EPID DOSIMETRY|MOTION MODEL|3D
        TUMOR-LOCALIZATION|X-RAY PROJECTION|dose assessment|respiratory motion|SBRT|treatment
        verification|4D cone beam CT</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>31</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26683530</PMID>\r\n    <WoSItemID>000369516600011</WoSItemID>\r\n
        \   <PublicationSourceTitle>PHYSICS IN MEDICINE AND BIOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>61</Volume>\r\n    <Issue>2</Issue>\r\n    <Pagination>554-568</Pagination>\r\n
        \   <PublicationDate>2016-01-21T00:00:00</PublicationDate>\r\n    <PublicationYear>2016</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Engineering,
        Biomedical|Radiology, Nuclear Medicine &amp; Medical Imaging</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0031-9155</ISSN>\r\n    <DOI>10.1088/0031-9155/61/2/554</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>4</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>IOP PUBLISHING
        LTD</CopyrightPublisher>\r\n    <CopyrightCity>BRISTOL</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.761,2014,ClosestToPublicationYear|2.761,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>21/76;ENGINEERING, BIOMEDICAL;2014;SC;ClosestToPublicationYear|34/125;RADIOLOGY,
        NUCLEAR MEDICINE &amp; MEDICAL IMAGING;2014;SC;ClosestToPublicationYear|21/76;ENGINEERING,
        BIOMEDICAL;2014;SC;MostRecentYear|34/125;RADIOLOGY, NUCLEAR MEDICINE &amp;
        MEDICAL IMAGING;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>74927691</PublicationItemID>\r\n
        \   <Title>Lung cancer treatment outcomes in recipients of lung transplant.</Title>\r\n
        \   <Abstract>BACKGROUND Lung transplant recipients develop lung cancer more
        commonly than the general population. The best treatment approach for these
        patients is unclear. The goal of this study is to evaluate treatment outcomes
        in this population.\r\nMETHODS We used the Cleveland Clinic lung transplant
        database to identify patients diagnosed with lung cancer at the time of or
        after lung transplant. Transplant and lung cancer-related data were retrospectively
        reviewed.\r\nRESULTS Among 847 patients underwent lung transplant between
        2005 and 2013, 17 (2%) were diagnosed with lung cancer and included. Median
        age was 61 (range, 48-70) years. Majority were stage I/II (n=11), one had
        stage IIIA, five had stage IV. Non-small cell lung cancer (NSCLC) were more
        common than small cell lung cancer (SCLC) (n=15 vs. 2). Curative treatment
        was performed as lobectomy in native lung (n=1), and radiation in transplanted
        lung (n=2). Chemotherapy was given in 10 patients, primarily carboplatin-based
        doublets with docetaxel, pemetrexed, or etoposide. Six of these received palliative
        chemotherapy for either metastases at diagnosis (n=3) or recurrence after
        early stage disease (n=3). Except for one patient with complete response,
        all others had progressive disease following palliative chemotherapy. Overall,
        patients who received chemotherapy had a median survival of 7.5 months from
        the initiation of chemotherapy, but 30% developed grade 5 sepsis. Median survival
        for stage I-IIIA and stage IV were 23.2 and 2.5 months respectively.\r\nCONCLUSIONS
        Lung cancer in lung transplant recipients carries various clinical courses.
        Patients with metastatic disease have substantial toxicities from chemotherapy
        and poor survival. Early stage patients should be offered treatment with modified
        dosages to decrease the risk of severe toxicities.</Abstract>\r\n    <AuthorList>Du,Lingling,|Pennell,Nathan,A|Elson,Paul,|Hashemi-Sadraei,Nooshin,</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList>Lung cancer|chemotherapy|lung
        transplant|outcome</KeywordList>\r\n    <DocumentTypeList>Journal Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>26798588</PMID>\r\n    <PublicationSourceTitle>Translational
        lung cancer research</PublicationSourceTitle>\r\n    <Volume>4</Volume>\r\n
        \   <Issue>6</Issue>\r\n    <Pagination>784-791</Pagination>\r\n    <PublicationDate>2015-12-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>2218-6751</ISSN>\r\n    <DOI>10.3978/j.issn.2218-6751.2015.12.08</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>5</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>CHINA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>74753108</PublicationItemID>\r\n
        \   <Title>TAREXTUMAB Anti-Notch 2/3 MAb Treatment of small cell lung cancer
        Treatment of pancreatic cancer</Title>\r\n    <Abstract>Notch (neurogenic
        locus notch homolog protein) signaling is a highly conserved pathway, with
        many roles at various stages during development. Interestingly, Notch is also
        a powerful stem cell-promoting pathway, which makes it a potential target
        for therapeutic strategies in many types of tumors due to the undifferentiated
        or de-differentiated state of cancer cells. Different approaches have been
        attempted to inhibit Notch signaling, including gamma-secretase inhibitors,
        alpha-secretase inhibitors and monoclonal antibodies targeting Notch family
        members. Of these antibodies against Notch, ligands such as delta-like protein
        4 have shown promising results as an antiangiogenic strategy. However, these
        have also been found to cause vascular or endothelial cell-based tumors after
        prolonged treatment in mice. Tarextumab (OMP-59R5) is a novel monoclonal antibody
        specifically targeting Notch 2/3, currently under active development by OncoMed
        Pharmaceuticals. Preclinical and clinical studies with this compound have
        shown promising results for this antibody, alone or in combination with standard
        chemotherapy, in various types of solid tumors including pancreatic cancer
        and small cell lung cancer. This is a review of the development of tarextumab,
        including main findings in both preclinical and clinical settings.</Abstract>\r\n
        \   <AuthorList>Marques,F,</AuthorList>\r\n    <AuthorCount>1</AuthorCount>\r\n
        \   <KeywordList>CELLS|INHIBITS TUMOR-GROWTH|SIGNALING PATHWAY|LUNG-CANCER|ANGIOGENESIS|EXPRESSION|DLL4|NUCLEAR
        NOTCH3|Notch signaling|pancreatic cancer|small cell lung cancer|OMP-59R5|Tarextumab</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>36</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000368416500002</WoSItemID>\r\n
        \   <PublicationSourceTitle>DRUGS OF THE FUTURE</PublicationSourceTitle>\r\n
        \   <Volume>40</Volume>\r\n    <Issue>12</Issue>\r\n    <Pagination>809-812</Pagination>\r\n
        \   <PublicationDate>2015-12-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Pharmacology
        &amp; Pharmacy</PublicationSubjectCategoryList>\r\n    <ISSN>0377-8282</ISSN>\r\n
        \   <DOI>10.1358/dof.2015.040.12.2420732</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>6</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>PROUS SCIENCE, SAU-THOMSON REUTERS</CopyrightPublisher>\r\n
        \   <CopyrightCity>BARCELONA</CopyrightCity>\r\n    <PublicationImpactFactorList>0.17,2014,ClosestToPublicationYear|0.17,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>253/254;PHARMACOLOGY &amp; PHARMACY;2014;SC;ClosestToPublicationYear|253/254;PHARMACOLOGY
        &amp; PHARMACY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>SPAIN</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>73915356</PublicationItemID>\r\n
        \   <Title>WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL
        PUBLIC VALUES (vol 31, pg 264, 2015)</Title>\r\n    <Abstract>Owing to an
        editorial error, in the article by Thongprasert et al. (1) in the August 2015
        issue of International Journal of Technical Assessment in Health Care, Bruce
        Crawford was incorrectly listed as the corresponding author. The corresponding
        author is Unchalee Permsuwan.</Abstract>\r\n    <AuthorList>Thongprasert,Sumitra,|Crawford,Bruce,|Sakulbumrungsil,Rungpetch,|Chaiyakunapruk,Nathorn,|Petcharapiruch,Sirinthip,|Leartsakulpanitch,Jittrakul,|Permsuwan,Unchalee,</AuthorList>\r\n
        \   <AuthorCount>7</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Correction</DocumentTypeList>\r\n
        \   <DocumentCategory>Other</DocumentCategory>\r\n    <NumberOfReferences>1</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000366655300015</WoSItemID>\r\n
        \   <PublicationSourceTitle>INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT
        IN HEALTH CARE</PublicationSourceTitle>\r\n    <Volume>31</Volume>\r\n    <Issue>4</Issue>\r\n
        \   <Pagination>271-271</Pagination>\r\n    <PublicationDate>2015-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Health Care Sciences &amp; Services|Public,
        Environmental &amp; Occupational Health|Medical Informatics</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0266-4623</ISSN>\r\n    <DOI>10.1017/S026646231500063X</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>7</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>CAMBRIDGE
        UNIV PRESS</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>1.308,2014,ClosestToPublicationYear|1.308,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>65/89;HEALTH CARE SCIENCES &amp; SERVICES;2014;SC;ClosestToPublicationYear|101/162;PUBLIC,
        ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH;2014;SC;ClosestToPublicationYear|18/24;MEDICAL
        INFORMATICS;2014;SC;ClosestToPublicationYear|65/89;HEALTH CARE SCIENCES &amp;
        SERVICES;2014;SC;MostRecentYear|101/162;PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL
        HEALTH;2014;SC;MostRecentYear|18/24;MEDICAL INFORMATICS;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>73861659</PublicationItemID>\r\n    <Title>China experts
        consensus on icotinib for non-small cell lung cancer treatment (2015 version).</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Shi,Yuankai,|Sun,Yan,|Ding,Cuimin,|Wang,Ziping,|Wang,Changli,|Wang,Zheng,|Bai,Chong,|Bai,Chunxue,|Feng,Jifeng,|Liu,Xiaoqing,|Li,Fang,|Yang,Yue,|Shu,Yongqian,|Wu,Milu,|He,Jianxing,|Zhang,Yiping,|Zhang,Shucai,|Chen,Gongyan,|Luo,Honghe,|Luo,Rongcheng,|Zhou,Caicun,|Zhou,Yanbin,|Pang,Qingsong,|Zhao,Hong,|Zhao,Qiong,|Gu,Aiqin,|Ling,Yang,|Huang,Cheng,|Han,Baohui,|Jiao,Shunchang,|Jiao,Hong,</AuthorList>\r\n
        \   <AuthorCount>31</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Journal
        Article|Review</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>26605306</PMID>\r\n
        \   <PublicationSourceTitle>Annals of translational medicine</PublicationSourceTitle>\r\n
        \   <Volume>3</Volume>\r\n    <Issue>18</Issue>\r\n    <Pagination>260-?</Pagination>\r\n
        \   <PublicationDate>2015-10-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationSubjectCategoryList />\r\n    <ISSN>2305-5839</ISSN>\r\n    <DOI>10.3978/j.issn.2305-5839.2015.10.30</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>8</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>CHINA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73856784</PublicationItemID>\r\n
        \   <Title>WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL
        PUBLIC VALUES</Title>\r\n    <Abstract>Objectives: Lung cancer has been the
        most common cancer since 1985, accounting for 12-13 percent of cancer cases
        worldwide. Newer targeted therapies with potential increased survival benefits
        may not be affordable to patients. Many countries use arbitrary thresholds
        to determine whether a medical intervention is cost-effective. As such, many
        effective, albeit expensive, therapies are not being reimbursed. To understand
        the value placed on effective therapies, this study evaluates the patient
        and public willingness to pay (WTP) for a quality-adjusted life-year (QALY)
        for lung cancer treatments using Thailand as an example.  Methods: A total
        of 300 subjects responded to hypothetical lung cancer health states, described
        by three levels of severity and two levels of side effects, and provided their
        valuation of the level of quality of life and their WTP to improve from one
        state to another.  Results: The patients with the lowest income and general
        public were willing to pay more than twice the threshold for acceptability
        in Thailand (US Dollar 5,123/QALY [Thai Baht 160,000/QALY]). This increased
        significantly by wealth category. Patients' WTP was associated with quality
        of life, financial difficulties, health insurance, diarrhea, and wealth.  Conclusions:
        The current study highlights the value patients and general public place on
        effective lung cancer therapies.</Abstract>\r\n    <AuthorList>Thongprasert,Sumitra,|Crawford,Bruce,|Sakulbumrungsil,Rungpetch,|Chaiyakunapruk,Nathorn,|Petcharapiruch,Sirinthip,|Leartsakulpanitch,Jittrakul,|Permsuwan,Unchalee,</AuthorList>\r\n
        \   <AuthorCount>7</AuthorCount>\r\n    <KeywordList>willingness-to-pay|lung
        cancer|health economics|cancer treatment|pharmacoeconomics</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>13</NumberOfReferences>\r\n
        \   <TimesCited>1</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26353902</PMID>\r\n    <WoSItemID>000366655300014</WoSItemID>\r\n
        \   <PublicationSourceTitle>INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT
        IN HEALTH CARE</PublicationSourceTitle>\r\n    <Volume>31</Volume>\r\n    <Issue>4</Issue>\r\n
        \   <Pagination>264-270</Pagination>\r\n    <PublicationDate>2015-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Health Care Sciences &amp; Services|Public,
        Environmental &amp; Occupational Health|Medical Informatics</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0266-4623</ISSN>\r\n    <DOI>10.1017/S0266462315000409</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>9</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>CAMBRIDGE
        UNIV PRESS</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>1.308,2014,ClosestToPublicationYear|1.308,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>65/89;HEALTH CARE SCIENCES &amp; SERVICES;2014;SC;ClosestToPublicationYear|101/162;PUBLIC,
        ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH;2014;SC;ClosestToPublicationYear|18/24;MEDICAL
        INFORMATICS;2014;SC;ClosestToPublicationYear|65/89;HEALTH CARE SCIENCES &amp;
        SERVICES;2014;SC;MostRecentYear|101/162;PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL
        HEALTH;2014;SC;MostRecentYear|18/24;MEDICAL INFORMATICS;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,1,0|2,1,0|3,1,0|4,1,0|5,1,0|6,1,0|7,1,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>73843960</PublicationItemID>\r\n    <Title>Immunotherapy:
        the third wave in lung cancer treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Heigener,David,Felix|Reck,Martin,</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList>DOCETAXEL|NIVOLUMAB|BMS-936558|ONO-4538</KeywordList>\r\n
        \   <DocumentTypeList>Editorial Material</DocumentTypeList>\r\n    <DocumentCategory>Other</DocumentCategory>\r\n
        \   <NumberOfReferences>7</NumberOfReferences>\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID>26679022</PMID>\r\n
        \   <WoSItemID>000365817900023</WoSItemID>\r\n    <PublicationSourceTitle>LANCET
        RESPIRATORY MEDICINE</PublicationSourceTitle>\r\n    <Volume>3</Volume>\r\n
        \   <Issue>12</Issue>\r\n    <Pagination>923-924</Pagination>\r\n    <PublicationDate>2015-12-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Critical Care Medicine|Respiratory System</PublicationSubjectCategoryList>\r\n
        \   <ISSN>2213-2600</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>10</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>ELSEVIER SCI LTD</CopyrightPublisher>\r\n    <CopyrightCity>OXFORD</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>9.629,2014,ClosestToPublicationYear|9.629,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>2/57;RESPIRATORY SYSTEM;2014;SC;ClosestToPublicationYear|2/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>OXON</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>73839029</PublicationItemID>\r\n    <Title>Cyclooxygenase-2
        inhibitors in lung cancer treatment: Bench to bed</Title>\r\n    <Abstract>The
        most common and leading cause of cancer-related death in men is lung cancer.
        Despite the recent advances in chemotherapy, advanced lung cancer still remains
        incurable. For this, the understanding of molecular mechanisms involved in
        lung carcinogenesis is necessary to provide potentially effective therapeutic
        targets for the treatment of lung cancer, and thus the therapeutic limitations
        can be overcome. Cyclooxygenase-2 (COX-2) is an important inflammation factor
        that is reported to be up-regulated in different cancers. A number of COX-2
        inhibitors have been developed, but most of them are restricted due to the
        different risk factors. Currently, the FDA has allowed celecoxib to remain
        on the market but advised physicians to apply this drug with alternative therapies
        or to use at a low dosage. Some other COX-2 inhibitors, such as, apricoxib
        and etoricoxib are under critical investigation currently. Celecoxib is being
        tested in clinical trials against lung cancer, as a single agent or in combination
        with other agents. Recent studies have suggested celecoxib as a feasible and
        clinically active regimen in the treatment of patients with lung cancer. However,
        more clinical trials are necessary for the better understanding of the role
        of selective COX-2 inhibitors in the prevention and treatment of lung cancer
        along with their assessment of toxicity. In this review, we have discussed
        the mechanism of actions of COX-2 in cancer progression and the therapeutic
        use of COX-2 inhibitors in the treatment of lung cancer with subsequent clinical
        studies and future management. (C) 2015 Elsevier B.V. All rights reserved.</Abstract>\r\n
        \   <AuthorList>Liu,Rui,|Xu,Kang-Ping,|Tan,Gui-Shan,</AuthorList>\r\n    <AuthorCount>3</AuthorCount>\r\n
        \   <KeywordList>PROGNOSTIC-SIGNIFICANCE|PANCREATIC-CANCER|PHASE-I|ENDOTHELIAL
        GROWTH-FACTOR|BREAST-CANCER|CELECOXIB INDUCES APOPTOSIS|COX-2 INHIBITION|PROSTATE-CANCER|CELL
        CARCINOMA|SELECTIVE CYCLO-OXYGENASE-2 INHIBITOR|cyclooxygenase-2|lung cancer|celecoxib|clinical
        trials|combination therapy</KeywordList>\r\n    <DocumentTypeList>Review</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>77</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26548623</PMID>\r\n    <WoSItemID>000366137800015</WoSItemID>\r\n
        \   <PublicationSourceTitle>EUROPEAN JOURNAL OF PHARMACOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>769</Volume>\r\n    <Pagination>127-133</Pagination>\r\n    <PublicationDate>2015-12-15T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Pharmacology &amp; Pharmacy</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0014-2999</ISSN>\r\n    <DOI>10.1016/j.ejphar.2015.11.007</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>11</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        SCIENCE BV</CopyrightPublisher>\r\n    <CopyrightCity>AMSTERDAM</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.532,2014,ClosestToPublicationYear|2.532,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>113/254;PHARMACOLOGY &amp; PHARMACY;2014;SC;ClosestToPublicationYear|113/254;PHARMACOLOGY
        &amp; PHARMACY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>NETHERLANDS</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73838152</PublicationItemID>\r\n
        \   <Title>Molecular profile of liquid biopsies: next generation biomarkers
        to improve lung cancer treatment.</Title>\r\n    <Abstract>Molecular profiling
        of liquid biopsies is now emerging as pivotal for cancer biomarker discovery.
        The low-invasive nature of the approach used for collecting biospecimens (i.e.
        blood, urine, saliva, etc.) may allow a widespread application of novel molecular
        diagnostics based on liquid biopsies. This is relevant, for example, in cancer
        screening programmes where it is essential to reduce costs and the complexity
        of screening tests in order to increase study compliance and effectiveness.
        Here, I discuss recent advances in biomarkers for the early cancer detection
        and prediction of chemotherapy response based on the molecular profiling of
        liquid biopsies. </Abstract>\r\n    <AuthorList>Bianchi,Fabrizio,</AuthorList>\r\n
        \   <AuthorCount>1</AuthorCount>\r\n    <KeywordList>biomarkers|circulating
        biomarkers|circulating tumour DNA|lung cancer|microRNA</KeywordList>\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>26635902</PMID>\r\n
        \   <PublicationSourceTitle>Ecancermedicalscience</PublicationSourceTitle>\r\n
        \   <Volume>9</Volume>\r\n    <Pagination>598-?</Pagination>\r\n    <PublicationDate>2015-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>1754-6605</ISSN>\r\n    <DOI>10.3332/ecancer.2015.598</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>12</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>73810735</PublicationItemID>\r\n    <Title>WILLINGNESS
        TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL PUBLIC VALUES-ERRATUM.</Title>\r\n
        \   <Abstract>Owing to an editorial error, in the article by Thongprasert
        et al. (1) in the August 2015 issue of International Journal of Technical
        Assessment in Health Care, Bruce Crawford was incorrectly listed as the corresponding
        author. The corresponding author is Unchalee Permsuwan. </Abstract>\r\n    <AuthorList
        />\r\n    <AuthorCount>0</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>26549552</PMID>\r\n
        \   <PublicationSourceTitle>International journal of technology assessment
        in health care</PublicationSourceTitle>\r\n    <Volume>31</Volume>\r\n    <Issue>4</Issue>\r\n
        \   <Pagination>271-?</Pagination>\r\n    <PublicationDate>2015-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>0266-4623</ISSN>\r\n    <DOI>10.1017/S026646231500063X</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>13</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <PublicationImpactFactorList>1.308,2014,ClosestToPublicationYear|1.308,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>65/89;HEALTH CARE SCIENCES &amp; SERVICES;2014;SC;ClosestToPublicationYear|101/162;PUBLIC,
        ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH;2014;SC;ClosestToPublicationYear|18/24;MEDICAL
        INFORMATICS;2014;SC;ClosestToPublicationYear|65/89;HEALTH CARE SCIENCES &amp;
        SERVICES;2014;SC;MostRecentYear|101/162;PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL
        HEALTH;2014;SC;MostRecentYear|18/24;MEDICAL INFORMATICS;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73798430</PublicationItemID>\r\n
        \   <Title>Lung cancer treatment rates and the role of the lung cancer nurse
        specialist: a qualitative study</Title>\r\n    <Abstract>Objectives This qualitative
        study examines how the Lung Cancer Nurse Specialist (LCNS) role operates and
        why they may be able to increase access to treatment.  Setting 4 Hospital
        NHS Foundation Trusts in England.  Design A multiple case study design using
        semistructured interviews, observation and Framework Analysis techniques.
        \ Participants Four LCNSs, comprised the cases'. Twenty four clinicians who
        worked with the LCNS participated in individual interviews. Six LCNSs took
        part in a group interview and 60 lung cancer multidisciplinary team (MDT)
        members and co-ordinators were observed in the MDT meeting.  Results The LCNS
        is crucial within the MDT and can act as a catalyst to patient access to treatment.
        The study identified the clinical activity (assessment, managing symptoms,
        psychological support and information provision) and role characteristics
        that can facilitate treatment access. These characteristics are the LCNS's
        presence across the patient pathway, acting as the hub' of the MDT, maintaining
        a holistic patient focus and working to an advanced level of practice. The
        findings indicate how factors may have a cumulative impact on treatment access.
        \ Conclusions If UK patient with lung cancer survival rates are to improve
        in line with comparable countries, we need to employ every advantage. This
        study demonstrates how the LCNS role may open doors to positive patient outcomes,
        including treatment. Further research is required to explore patients' experiences,
        decision-making and attitudes to treatment.</Abstract>\r\n    <AuthorList>Tod,Angela,Mary|Redman,Judy,|McDonnell,Ann,|Borthwick,Diana,|White,John,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList>qualitative research</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>26</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26685023</PMID>\r\n    <WoSItemID>000368839100037</WoSItemID>\r\n
        \   <PublicationSourceTitle>BMJ OPEN</PublicationSourceTitle>\r\n    <Volume>5</Volume>\r\n
        \   <Issue>12</Issue>\r\n    <Pagination />\r\n    <PublicationDate>2015-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Medicine, General &amp; Internal</PublicationSubjectCategoryList>\r\n
        \   <ISSN>2044-6055</ISSN>\r\n    <DOI>10.1136/bmjopen-2015-008587</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>14</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>BMJ PUBLISHING
        GROUP</CopyrightPublisher>\r\n    <CopyrightCity>LONDON</CopyrightCity>\r\n
        \   <ArticleNumber>e008587</ArticleNumber>\r\n    <PublicationImpactFactorList>2.271,2014,ClosestToPublicationYear|2.271,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>40/153;MEDICINE, GENERAL &amp; INTERNAL;2014;SC;ClosestToPublicationYear|40/153;MEDICINE,
        GENERAL &amp; INTERNAL;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73787238</PublicationItemID>\r\n
        \   <Title>China experts consensus on icotinib for non-small cell lung cancer
        treatment (2015 version)</Title>\r\n    <Abstract />\r\n    <AuthorList>Shi,Yuankai,|Sun,Yan,|Ding,Cuimin,|Wang,Ziping,|Wang,Changli,|Wang,Zheng,|Bai,Chong,|Bai,Chunxue,|Feng,Jifeng,|Liu,Xiaoqing,|Li,Fang,|Yang,Yue,|Shu,Yongqian,|Wu,Milu,|He,Jianxing,|Zhang,Yiping,|Zhang,Shucai,|Chen,Gongyan,|Luo,Honghe,|Luo,Rongcheng,|Zhou,Caicun,|Zhou,Yanbin,|Pang,Qingsong,|Zhao,Hong,|Zhao,Qiong,|Gu,Aiqin,|Ling,Yang,|Huang,Cheng,|Han,Baohui,|Jiao,Shunchang,|Jiao,Hong,</AuthorList>\r\n
        \   <AuthorCount>31</AuthorCount>\r\n    <KeywordList>OPEN-LABEL|III TRIAL|1ST-LINE
        TREATMENT|EGFR MUTATIONS|CHEMOTHERAPY|ADENOCARCINOMA|ERLOTINIB|GEFITINIB|MULTICENTER|RANDOMIZED
        PHASE-3 TRIAL</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>28</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26623122</PMID>\r\n    <WoSItemID>000366486700007</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF THORACIC DISEASE</PublicationSourceTitle>\r\n
        \   <Volume>7</Volume>\r\n    <Issue>10</Issue>\r\n    <Pagination>E468-E472</Pagination>\r\n
        \   <PublicationDate>2015-10-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Respiratory
        System</PublicationSubjectCategoryList>\r\n    <ISSN>2072-1439</ISSN>\r\n
        \   <DOI>10.3978/j.issn.2072-1439.2015.10.25</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>15</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>PIONEER BIOSCIENCE PUBL CO</CopyrightPublisher>\r\n
        \   <CopyrightCity>HONG KONG</CopyrightCity>\r\n    <PublicationImpactFactorList>1.783,2014,ClosestToPublicationYear|1.783,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>42/57;RESPIRATORY SYSTEM;2014;SC;ClosestToPublicationYear|42/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0|10,0,0|11,0,0|12,0,0|13,0,0|14,0,0|15,0,0|16,0,0|17,0,0|18,0,0|19,0,0|20,0,0|21,0,0|22,0,0|23,0,0|24,0,0|25,0,0|26,0,0|27,0,0|28,0,0|29,0,0|30,0,0|31,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>CHINA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73649088</PublicationItemID>\r\n
        \   <Title>Dosimetric verification of stereotactic body radiation therapy
        for lung cancer treatment plans using flattening filter-free beams</Title>\r\n
        \   <Abstract>Aims: This study aimed to analyze the dose distribution using
        different dosimetric tools in conducting pretreatment quality assurance for
        lung cancer stereotactic body radiation therapy (SBRT) plans with flattening
        filter free (FFF) beams.  Methods: Nine patients with lung cancer treated
        via SBRT were randomly selected, and their treatment plans were generated
        using the Eclipse treatment planning system (TPS) with FFF beams. For each
        patient, the same plan was applied to the Delta4 phantom and MatriXX by the
        TPS, which calculated the dose distribution. The Delta4 and MatriXX phantoms
        were then used to measure the actual dose distribution at the linear accelerator,
        and these measured doses were compared to with the calculated doses. Gamma
        analysis was employed in verifying the correspondence between the dose distributions.
        The absolute point doses were measured by a 0.016 mL Microchamber with the
        RW3 phantom and Thorax phantom.  Results: The absolute point doses measured
        by the 0.016 mL Microchamber were within 3% of the calculated results for
        the central point of the RW3 and Thorax phantoms. The Delta4 and MatriXX dose
        distributions agreed well with the measured and calculated doses, over 98%,
        based on the 3% maximum dose and 3 mm gamma criteria.  Conclusions: Both measured
        and calculated doses for the Delta4 and MatriXX phantoms agreed well for each
        patient with lung cancer. The absolute point dose measurements using the 0.016
        mL Microchamber exhibited excellent agreement with the TPS calculated between
        the RW3 and Thorax phantoms.</Abstract>\r\n    <AuthorList>Zhang,Jiyong,|Wu,Vincent,W|Lu,Jiayang,|Hong,Danli,|Lin,Zhixiong,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList>DELIVERY|QUALITY-ASSURANCE|IONIZATION-CHAMBER|ARRAY|RADIOTHERAPY|TUMORS|OUTCOMES|QA|CLINICAL
        ROUTINE|RAPIDARC|lung cancer|dosimetric verification|stereotactic body radiation
        therapy|Delta4|flattening filter free|MatriXX</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>25</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26108236</PMID>\r\n    <WoSItemID>000371185700007</WoSItemID>\r\n
        \   <PublicationSourceTitle>TUMORI</PublicationSourceTitle>\r\n    <Volume>101</Volume>\r\n
        \   <Issue>6</Issue>\r\n    <Pagination>631-636</Pagination>\r\n    <PublicationDate>2015-11-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0300-8916</ISSN>\r\n    <DOI>10.5301/tj.5000363</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>16</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>WICHTIG PUBL</CopyrightPublisher>\r\n    <CopyrightCity>MILAN</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>1.269,2014,ClosestToPublicationYear|1.269,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>183/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|183/211;ONCOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>ITALY</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73645725</PublicationItemID>\r\n
        \   <Title>Evaluation of melanoma antigen gene A3 expression in drug resistance
        of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced
        nonsmall cell lung cancer treatment.</Title>\r\n    <Abstract>OBJECTIVE To
        investigate the correlation between melanoma antigen gene A3 (MAGE-A3) expression
        and progression-free survival (PFS) of nonsmall cell lung cancer (NSCLC) patients
        with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs)
        therapy, aiming to provide a basis for research and treatment of EGFR-TKIs
        resistance.\r\nRESEARCH AND METHODS Retrospective analysis is conducted of
        PFS of 359 NSCLC patients who have been tested positive for EGFR, and experienced
        drug resistance during oral treatment of icotinib. MAGE-A3 expression is tested
        using immunology and histology chemistry methods, and T790M and c-MeT expression
        are tested using mutation-enriched polymerase chain reaction.\r\nRESULTS (1)
        MAGE-A3 expression in targeted treatment of NSCLC patients shows a positive
        rate of 33.98%. The comparative difference between MAGE-A3 expression and
        T790M, c-MeT and other resistance genes was not statistically significant
        (P &gt; 0.05). (2) MAGE-A3 expression was higher in patients with NSCLC targeted
        therapy of primary drug resistance of positive rate than acquired resistance;
        meanwhile the expression level differences in three modes of acquired resistance
        are statistically significant (P &lt; 0.05). (3) PFS of MAGE-A3 positive expression
        in the targeted treatment of acquired drug resistance in patients with NSCLC
        is shorter than the PFS of MAGE-A3 negative expression (P = 0.01); the comparative
        PFS differences in the three kinds of acquired drug resistance pattern have
        statistical significance (P = 0.02). (4) PFS and levels of MAGE-A3 expression
        in NSCLC patients with the three modes of acquired resistance are negatively
        correlated (P &lt; 0.01), and MAGE-A3 expression has no correlation with age,
        gender, pathological type or PS score (P &gt; 0.05).\r\nCONCLUSION MAGE-A3
        expression in EGFR-TKIs target therapy in NSCLC patient suggests that there
        might be EGFR-TKIs drug resistance, and the higher the level of expression,
        the shorter the time of acquired drug resistance.</Abstract>\r\n    <AuthorList>Jin,Ju,|Liu,Bang-Zhu,|Wu,Zhuo-Min,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>26612451</PMID>\r\n
        \   <PublicationSourceTitle>Journal of cancer research and therapeutics</PublicationSourceTitle>\r\n
        \   <Volume>11</Volume>\r\n    <Pagination>C271-4</Pagination>\r\n    <PublicationDate>2015-11-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>1998-4138</ISSN>\r\n    <DOI>10.4103/0973-1482.170549</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>17</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <PublicationImpactFactorList>0.791,2014,ClosestToPublicationYear|0.791,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>197/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|197/211;ONCOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>INDIA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73609753</PublicationItemID>\r\n
        \   <Title>DEVELOPMENT OF A DRY POWDER INHALER FORMULATION OF CURCUMIN FOR
        LUNG CANCER TREATMENT</Title>\r\n    <Abstract />\r\n    <AuthorList>AL Ayoub,Yuosef,|Assi,Khaled,|Paradkar,Anant,|Amin,Mohammad,</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000363934900134</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG
        DELIVERY</PublicationSourceTitle>\r\n    <Volume>28</Volume>\r\n    <Issue>3</Issue>\r\n
        \   <Pagination>A40-A40</Pagination>\r\n    <PublicationDate>2015-06-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Respiratory System</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1941-2711</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>18</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>MARY ANN LIEBERT, INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW
        ROCHELLE</CopyrightCity>\r\n    <PublicationImpactFactorList>2.798,2014,ClosestToPublicationYear|2.798,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>21/57;RESPIRATORY SYSTEM;2014;SC;ClosestToPublicationYear|21/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>73527443</PublicationItemID>\r\n    <Title>Lung Cancer
        Treatment Drug Bruceine B Affects the Pharmacokinetics of Warfarin</Title>\r\n
        \   <Abstract>Bruceine B is a potential drug being developed for lung cancer
        treatment, and high risk of blood clots was accompanied in-the cancer patients,
        and many cancer patients are using warfarin The present study aims to determine
        the influence of lung cancer treatment drug bruceine B towards the pharmacokinetics
        of warfarin. The structure of bruceine B was drawn using Chemdraw software.
        The crystal structure of CYP2C9 was obtained from RCSB protein data bank.
        Different crystal structures of CYP2C9 can be found in this PDB, among which,
        the crystal structure of CYP2C9 bound with warfarin (code: 1OG2) was selected
        in this study. Based on the orders of scoring values, the most suitable binding
        conformation was chosen among the top 20 poses. The distance between the metabolic
        site and catalytic center of CYP2C9 was 3.96 angstrom, and the interaction
        amino acids residue was Ile302. When co-docking bruceine B and warfarin into
        the activity cavity of CYP2C9, bruceine B exerted closer distance than warfatin
        towards CYP2C9. In conclusion, the effect of lung cancer treatment drug bruceine
        B towards the pharmacokinetics of warfarin was demonstrated in this work,
        which will benefit the development of bruceine B as the drug for lung cancer.</Abstract>\r\n
        \   <AuthorList>Xia,Yu,|Zhao,Xin,|Yan,Fan,|Jiao,Kegang,|Tuohayi,Jiazina,|Wushouer,Qimanguli,</AuthorList>\r\n
        \   <AuthorCount>6</AuthorCount>\r\n    <KeywordList>APOPTOSIS|GLUCURONIDATION|molecular
        docking|bruceine B|cytochrome P450 (CYP) 2C9</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>9</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000364271100032</WoSItemID>\r\n
        \   <PublicationSourceTitle>LATIN AMERICAN JOURNAL OF PHARMACY</PublicationSourceTitle>\r\n
        \   <Volume>34</Volume>\r\n    <Issue>7</Issue>\r\n    <Pagination>1473-1475</Pagination>\r\n
        \   <PublicationDate>2015-09-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Pharmacology
        &amp; Pharmacy</PublicationSubjectCategoryList>\r\n    <ISSN>0326-2383</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>19</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>COLEGIO
        FARMACEUTICOS PROVINCIA DE BUENOS AIRES</CopyrightPublisher>\r\n    <CopyrightCity>LA
        PLATA</CopyrightCity>\r\n    <PublicationImpactFactorList>0.372,2014,ClosestToPublicationYear|0.372,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>246/254;PHARMACOLOGY &amp; PHARMACY;2014;SC;ClosestToPublicationYear|246/254;PHARMACOLOGY
        &amp; PHARMACY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>ARGENTINA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n</ArrayOfPublicationItem>"
    http_version: 
  recorded_at: Tue, 05 Apr 2016 23:40:17 GMT
- request:
    method: get
    uri: https://sciencewirerest.discoverylogic.com/PublicationCatalog/PublicationQuery/50106?format=xml&page=0&pageSize=2147483647&v=version/4
    body:
      encoding: UTF-8
      string: ''
    headers:
      User-Agent:
      - Faraday v0.9.2
      Accept:
      - "*/*"
      Accept-Encoding:
      - gzip,deflate
      Date:
      - Wed, 04 May 2016 00:38:36 GMT
      Licenseid:
      - Settings.SCIENCEWIRE.LICENSE_ID
      Host:
      - Settings.SCIENCEWIRE.HOST
      Connection:
      - Keep-Alive
      Expect:
      - 100-continue
      Content-Type:
      - text/xml
  response:
    status:
      code: 200
      message: OK
    headers:
      Cache-Control:
      - private
      Content-Type:
      - application/xml; charset=utf-8
      Server:
      - Microsoft-IIS/7.5
      X-Aspnetmvc-Version:
      - '2.0'
      X-Aspnet-Version:
      - 4.0.30319
      X-Powered-By:
      - ASP.NET
      Date:
      - Wed, 04 May 2016 00:38:37 GMT
      Content-Length:
      - '60436'
    body:
      encoding: UTF-8
      string: "<?xml version=\"1.0\"?>\r\n<ArrayOfPublicationItem xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\"
        xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75618307</PublicationItemID>\r\n    <Title>Timing in
        initiating lung cancer treatment after bronchoscopy in France: Study from
        medico-administrative database.</Title>\r\n    <Abstract>BACKGROUND Time-to-treatment
        of cancer is becoming a serious political and social issue. A greater understanding
        of the timeframes involved in cancer care is needed to reduce inequalities
        in access to care caused by delays.\r\nOBJECTIVE To describe time delays in
        each phase of lung cancer treatment after bronchoscopy.\r\nMETHOD Using the
        international classification of diseases and medical procedures codes, from
        national hospital discharge database we selected patients newly diagnosed
        for Lung cancer in 2009-2010 who had undergone treatment.\r\nRESULTS We included
        14,596 patients. Median times from bronchoscopy to 1) neo-adjuvant chemotherapy
        and to surgery in patients with surgical pathway were 34d (Q25=22; Q75=47)
        and 44d (Q25=26; Q75=82), respectively, 2) chemotherapy and to radiotherapy
        in patients with non-surgical pathway, were 33d (Q25=22; Q75=49) and 88d (Q25=46;
        Q75=162) respectively, 3) first treatment irrespective of pathway and treatment
        combination was 34d (Q25=22; Q75=50). Time to first treatment was significantly
        higher with age and with the status of the first care center. It was longer
        in most northern regions and in overseas districts and shorter in southern
        and eastern regions of the country.\r\nCONCLUSION To our knowledge, this is
        the first study based on medico-administrative database describing time to
        first treatment after bronchoscopy in patients suffering from lung cancer
        in France. It could inform decision-making on guidelines on times to access
        lung cancer treatment.</Abstract>\r\n    <AuthorList>Kudjawu,Yao,Cyril|Chatellier,Gilles,|Decool,Elsa,|de
        Maria,Florence,|Beltzer,Nathalie,|Grmy,Isabelle,|Meyer,Guy,|Eilstein,Daniel,</AuthorList>\r\n
        \   <AuthorCount>8</AuthorCount>\r\n    <KeywordList>Bronchoscopy|Hospital-discharge
        database|Lung neoplasm|Time-to-treatment</KeywordList>\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>27040851</PMID>\r\n
        \   <PublicationSourceTitle>Lung cancer </PublicationSourceTitle>\r\n    <Volume>95</Volume>\r\n
        \   <Pagination>44-50</Pagination>\r\n    <PublicationDate>2016-05-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2016</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>0169-5002</ISSN>\r\n    <DOI>10.1016/j.lungcan.2016.02.016</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>0</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        IRELAND LTD</CopyrightPublisher>\r\n    <CopyrightCity />\r\n    <PublicationImpactFactorList>3.958,2014,ClosestToPublicationYear|3.958,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>59/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|12/57;RESPIRATORY
        SYSTEM;2014;SC;ClosestToPublicationYear|59/211;ONCOLOGY;2014;SC;MostRecentYear|12/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>IRELAND</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>75564620</PublicationItemID>\r\n
        \   <Title>DEMCIZUMAB Anti-DLL4 monoclonal antibody Treatment of non-small
        cell lung cancer Treatment of pancreatic cancer</Title>\r\n    <Abstract>Demcizumab
        (OMP-21M18) is a novel anti-DLL4 (delta-like protein 4) humanized monoclonal
        antibody (MAb) developed by researchers at OncoMed Pharmaceuticals. In preclinical
        studies demcizumab demonstrated the ability to block Notch signaling and inhibit
        tumor growth through multiple mechanisms, such as the reduction of cancer
        stem cell frequency and the inhibition of angiogenesis. Phase I data demonstrated
        that demcizumab was generally well tolerated and had promising antitumor activity
        in patients with advanced solid tumors. This anti-DLL4 MAb is currently being
        tested in additional phase I and phase II studies in combination with gemcitabine
        with or without nab-paclitaxel in pancreatic cancer, with FOLFIRI in colorectal
        cancer, with carboplatin and pemetrexed in lung cancer and with paclitaxel
        in patients with platinum-resistant ovarian cancer.</Abstract>\r\n    <AuthorList>Gajdosik,Z,</AuthorList>\r\n
        \   <AuthorCount>1</AuthorCount>\r\n    <KeywordList>CELLS|TUMOR|ANTI-DLL4|NSCLC|pancreatic
        cancer|OMP-21M18|demcizumab|Anti-DLL4</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>16</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000373119400001</WoSItemID>\r\n
        \   <PublicationSourceTitle>DRUGS OF THE FUTURE</PublicationSourceTitle>\r\n
        \   <Volume>41</Volume>\r\n    <Issue>1</Issue>\r\n    <Pagination>5-8</Pagination>\r\n
        \   <PublicationDate>2016-01-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2016</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Pharmacology
        &amp; Pharmacy</PublicationSubjectCategoryList>\r\n    <ISSN>0377-8282</ISSN>\r\n
        \   <DOI>10.1358/dof.2016.041.01.2443234</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>1</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>PROUS SCIENCE, SAU-THOMSON REUTERS</CopyrightPublisher>\r\n
        \   <CopyrightCity>BARCELONA</CopyrightCity>\r\n    <PublicationImpactFactorList>0.17,2014,ClosestToPublicationYear|0.17,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>253/254;PHARMACOLOGY &amp; PHARMACY;2014;SC;ClosestToPublicationYear|253/254;PHARMACOLOGY
        &amp; PHARMACY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>SPAIN</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>75502195</PublicationItemID>\r\n
        \   <Title>Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics
        and New Frontiers (vol 30, pg 191 , 2013)</Title>\r\n    <Abstract />\r\n
        \   <AuthorList>Scheff,Ronald,J|Schneider,Bryan,J</AuthorList>\r\n    <AuthorCount>2</AuthorCount>\r\n
        \   <KeywordList />\r\n    <DocumentTypeList>Correction</DocumentTypeList>\r\n
        \   <DocumentCategory>Other</DocumentCategory>\r\n    <NumberOfReferences>1</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000209671100001</WoSItemID>\r\n
        \   <PublicationSourceTitle>SEMINARS IN INTERVENTIONAL RADIOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>30</Volume>\r\n    <Issue>2</Issue>\r\n    <Pagination>E1-E1</Pagination>\r\n
        \   <PublicationDate>2013-06-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2013</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Radiology,
        Nuclear Medicine &amp; Medical Imaging</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0739-9529</ISSN>\r\n    <DOI>10.1055/s-0033-1349396</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>2</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>THIEME MEDICAL PUBL INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW
        YORK</CopyrightCity>\r\n    <PublicationImpactFactorList>0.16,2000,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>77/80;RADIOLOGY, NUCLEAR MEDICINE &amp;
        MEDICAL IMAGING;2000;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n
        \   <CopyrightCountry>UNITED STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>75436672</PublicationItemID>\r\n
        \   <Title>Vitamin E TPGS conjugated carbon nanotubes improved efficacy of
        docetaxel with safety for lung cancer treatment.</Title>\r\n    <Abstract>The
        aim of this work was to develop multi-walled carbon nanotubes (MWCNT), which
        were coated or covalently conjugated with d-alpha-tocopheryl polyethylene
        glycol 1000 succinate (TPGS), and loaded docetaxel as a model drug for effective
        treatment to lung cancer in comparison with the commercial docetaxel injection
        (Docel). The human lung cancer cells (A549 cells) were employed as an in-vitro
        model to access cellular uptake, cytotoxicity, cellular apoptosis, cell cycle
        analysis, and reactive oxygen species (ROS) study of the docetaxel/coumarin-6
        loaded MWCNT. The safety of MWCNT formulations were studied by the measurements
        of alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and total protein
        levels in bronchoalveolar lavage (BAL) fluid of rats after the treatments.
        The IC50 values demonstrated that the TPGS conjugated MWCNT could be 80 folds
        more effective than Docel after 24h treatment with the A549 cells. Flow cytometry
        analysis confirmed that cancerous cells were appeared significantly (P&lt;0.05)
        in the sub G1 phase for TPGS conjugated MWCNT. Results of TPGS conjugated
        MWCNT have showed better efficacy with safety than non-coated or TPGS coated
        MWCNT and Docel. </Abstract>\r\n    <AuthorList>Singh,Rahul,Pratap|Sharma,Gunjan,|SONALI,,|Singh,Sanjay,|Kumar,Mohan,|Pandey,Bajarangprasad,L|Koch,Biplob,|Muthu,Madaswamy,S</AuthorList>\r\n
        \   <AuthorCount>8</AuthorCount>\r\n    <KeywordList>Lung cancer|MWCNT|Nanomedicine|Nanotechnology|ROS
        level|Safety|TPGS conjugation</KeywordList>\r\n    <DocumentTypeList>Journal
        Article</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>26895505</PMID>\r\n
        \   <PublicationSourceTitle>Colloids and surfaces. B, Biointerfaces</PublicationSourceTitle>\r\n
        \   <Volume>141</Volume>\r\n    <Pagination>429-442</Pagination>\r\n    <PublicationDate>2016-05-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2016</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>0927-7765</ISSN>\r\n    <DOI>10.1016/j.colsurfb.2016.02.011</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>3</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        B.V</CopyrightPublisher>\r\n    <CopyrightCity />\r\n    <PublicationImpactFactorList>4.152,2014,ClosestToPublicationYear|4.152,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>16/73;BIOPHYSICS;2014;SC;ClosestToPublicationYear|34/139;CHEMISTRY,
        PHYSICAL;2014;SC;ClosestToPublicationYear|8/33;MATERIALS SCIENCE, BIOMATERIALS;2014;SC;ClosestToPublicationYear|16/73;BIOPHYSICS;2014;SC;MostRecentYear|34/139;CHEMISTRY,
        PHYSICAL;2014;SC;MostRecentYear|8/33;MATERIALS SCIENCE, BIOMATERIALS;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>NETHERLANDS</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>75425606</PublicationItemID>\r\n
        \   <Title>CRM1 is overexpressed in lung tumorigenesis and represents an adjuvant
        target for lung cancer treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Gao,Weimin,|Lu,Chuanwen,|Chen,Lixia,|Keohavong,Phouthone,</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000371578503213</WoSItemID>\r\n
        \   <PublicationSourceTitle>CANCER RESEARCH</PublicationSourceTitle>\r\n    <Volume>75</Volume>\r\n
        \   <Pagination />\r\n    <PublicationDate>2015-08-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0008-5472</ISSN>\r\n    <DOI>10.1158/1538-7445.AM2015-1726</DOI>\r\n
        \   <ConferenceTitle>106th Annual Meeting of the American-Association-for-Cancer-Research
        (AACR)</ConferenceTitle>\r\n    <ConferenceStartDate>2015-04-18T00:00:00</ConferenceStartDate>\r\n
        \   <ConferenceEndDate>2015-04-22T00:00:00</ConferenceEndDate>\r\n    <ConferenceCity>PHILADELPHIA</ConferenceCity>\r\n
        \   <ConferenceStateCountry>PA</ConferenceStateCountry>\r\n    <Rank xsi:nil=\"true\"
        />\r\n    <OrdinalRank>4</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>AMER ASSOC CANCER RESEARCH</CopyrightPublisher>\r\n
        \   <CopyrightCity>PHILADELPHIA</CopyrightCity>\r\n    <PublicationImpactFactorList>9.329,2014,ClosestToPublicationYear|9.329,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>11/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|11/211;ONCOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>PA</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75405991</PublicationItemID>\r\n    <Title>Early-Stage
        Lung Cancer Treatment and Survival: Impact of Race</Title>\r\n    <Abstract
        />\r\n    <AuthorList>Williams,Christina,D|Kelley,Michael,J</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList>surgery|survival|disparity|race|radiotherapy</KeywordList>\r\n
        \   <DocumentTypeList>Meeting Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference
        Proceeding Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\"
        />\r\n    <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000370365101058</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>10</Volume>\r\n    <Issue>9</Issue>\r\n    <Pagination>S281-S281</Pagination>\r\n
        \   <PublicationDate>2015-09-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology|Respiratory
        System</PublicationSubjectCategoryList>\r\n    <ISSN>1556-0864</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>5</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>5.282,2014,ClosestToPublicationYear|5.282,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>30/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;ClosestToPublicationYear|30/211;ONCOLOGY;2014;SC;MostRecentYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75398481</PublicationItemID>\r\n    <Title>Fatal and
        near Fatal Radiation Lung Injury after Lung Cancer Treatment</Title>\r\n    <Abstract
        />\r\n    <AuthorList>Son,Choonhee,|Roh,Mee,Sook|Um,Soo-Jung,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList>interstitial lung disease|radiation
        pneumonitis</KeywordList>\r\n    <DocumentTypeList>Meeting Abstract</DocumentTypeList>\r\n
        \   <DocumentCategory>Conference Proceeding Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID xsi:nil=\"true\"
        />\r\n    <WoSItemID>000370365103303</WoSItemID>\r\n    <PublicationSourceTitle>JOURNAL
        OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n    <Volume>10</Volume>\r\n
        \   <Issue>9</Issue>\r\n    <Pagination>S687-S687</Pagination>\r\n    <PublicationDate>2015-09-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology|Respiratory System</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1556-0864</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>6</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>ELSEVIER SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW
        YORK</CopyrightCity>\r\n    <PublicationImpactFactorList>5.282,2014,ClosestToPublicationYear|5.282,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>30/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;ClosestToPublicationYear|30/211;ONCOLOGY;2014;SC;MostRecentYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75383106</PublicationItemID>\r\n    <Title>Importance
        of Exercise in Lung Cancer Treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Michaels,Carol,</AuthorList>\r\n
        \   <AuthorCount>1</AuthorCount>\r\n    <KeywordList>exercise|physical activity|benefits
        of physical activity for lung cancer patients|importance of exercise for lung
        cancer survivors</KeywordList>\r\n    <DocumentTypeList>Meeting Abstract</DocumentTypeList>\r\n
        \   <DocumentCategory>Conference Proceeding Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID xsi:nil=\"true\"
        />\r\n    <WoSItemID>000370365100049</WoSItemID>\r\n    <PublicationSourceTitle>JOURNAL
        OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n    <Volume>10</Volume>\r\n
        \   <Issue>9</Issue>\r\n    <Pagination>S88-S88</Pagination>\r\n    <PublicationDate>2015-09-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Oncology|Respiratory System</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1556-0864</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>7</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\" />\r\n
        \   <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>ELSEVIER SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW
        YORK</CopyrightCity>\r\n    <PublicationImpactFactorList>5.282,2014,ClosestToPublicationYear|5.282,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>30/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;ClosestToPublicationYear|30/211;ONCOLOGY;2014;SC;MostRecentYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75366198</PublicationItemID>\r\n    <Title>Quality
        of Lung Cancer Treatment in Two Neighbouring Regions of Germany and Denmark</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Storm,Hans,H|Engholm,Gerda,|Pritzkuleit,Ron,|Kejs,Anne,Mette
        T|Katalinic,Alexander,|Dunst,Juergen,|Hollaender,Niels,Henrik</AuthorList>\r\n
        \   <AuthorCount>7</AuthorCount>\r\n    <KeywordList>lung cancer|population
        based|stage specific|survival-benchmarking</KeywordList>\r\n    <DocumentTypeList>Meeting
        Abstract</DocumentTypeList>\r\n    <DocumentCategory>Conference Proceeding
        Document</DocumentCategory>\r\n    <NumberOfReferences xsi:nil=\"true\" />\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000370365101121</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF THORACIC ONCOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>10</Volume>\r\n    <Issue>9</Issue>\r\n    <Pagination>S303-S303</Pagination>\r\n
        \   <PublicationDate>2015-09-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology|Respiratory
        System</PublicationSubjectCategoryList>\r\n    <ISSN>1556-0864</ISSN>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>8</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>ELSEVIER
        SCIENCE INC</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>5.282,2014,ClosestToPublicationYear|5.282,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>30/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;ClosestToPublicationYear|30/211;ONCOLOGY;2014;SC;MostRecentYear|7/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75315890</PublicationItemID>\r\n    <Title>Evaluation
        of melanoma antigen gene A3 expression in drug resistance of epidermal growth
        factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung
        cancer treatment</Title>\r\n    <Abstract>Objective: To investigate the correlation
        between melanoma antigen gene A3 (MAGE-A3) expression and progression-free
        survival (PFS) of nonsmall cell lung cancer (NSCLC) patients with epidermal
        growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) therapy, aiming
        to provide a basis for research and treatment of EGFR-TKIs resistance. Research
        and Methods: Retrospective analysis is conducted of PFS of 359 NSCLC patients
        who have been tested positive for EGFR, and experienced drug resistance during
        oral treatment of icotinib. MAGE-A3 expression is tested using immunology
        and histology chemistry methods, and T790M and c-MeT expression are tested
        using mutation-enriched polymerase chain reaction. Results: (1) MAGE-A3 expression
        in targeted treatment of NSCLC patients shows a positive rate of 33.98%. The
        comparative difference between MAGE-A3 expression and T790M, c-MeT and other
        resistance genes was not statistically significant (P &gt; 0.05). (2) MAGE-A3
        expression was higher in patients with NSCLC targeted therapy of primary drug
        resistance of positive rate than acquired resistance; meanwhile the expression
        level differences in three modes of acquired resistance are statistically
        significant (P &lt; 0.05). (3) PFS of MAGE-A3 positive expression in the targeted
        treatment of acquired drug resistance in patients with NSCLC is shorter than
        the PFS of MAGE-A3 negative expression (P = 0.01); the comparative PFS differences
        in the three kinds of acquired drug resistance pattern have statistical significance
        (P = 0.02). (4) PFS and levels of MAGE-A3 expression in NSCLC patients with
        the three modes of acquired resistance are negatively correlated (P &lt; 0.01),
        and MAGE-A3 expression has no correlation with age, gender, pathological type
        or PS score (P &gt; 0.05). Conclusion: MAGE-A3 expression in EGFR-TKIs target
        therapy in NSCLC patient suggests that there might be EGFR-TKIs drug resistance,
        and the higher the level of expression, the shorter the time of acquired drug
        resistance.</Abstract>\r\n    <AuthorList>Jin,Ju,|Liu,Bang-Zhu,|Wu,Zhuo-Min,</AuthorList>\r\n
        \   <AuthorCount>3</AuthorCount>\r\n    <KeywordList>CARCINOMA|DOCETAXEL|GEFITINIB|lung
        cancer|drug resistance|target therapy|Melanoma antigen gene-A3</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>9</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000370873700009</WoSItemID>\r\n
        \   <PublicationSourceTitle>JOURNAL OF CANCER RESEARCH AND THERAPEUTICS</PublicationSourceTitle>\r\n
        \   <Volume>11</Volume>\r\n    <Issue>8</Issue>\r\n    <Pagination>271-274</Pagination>\r\n
        \   <PublicationDate>2015-11-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0973-1482</ISSN>\r\n    <DOI>10.4103/0973-1482.170549</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>9</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>MEDKNOW
        PUBLICATIONS &amp; MEDIA PVT LTD</CopyrightPublisher>\r\n    <CopyrightCity>MUMBAI</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>0.791,2014,ClosestToPublicationYear|0.791,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>197/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|197/211;ONCOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>INDIA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>75210085</PublicationItemID>\r\n
        \   <Title>On the pharmacogenetics of non-small cell lung cancer treatment</Title>\r\n
        \   <Abstract>Introduction. Despite many clinical efforts, non-small-cell
        lung cancer (NSCLC) has a dismal 5-year survival rate of 16%, and high incidence
        of recurrence. The success of biologically targeted agents, as well as the
        activity of well-established chemotherapeutic regimens, has been limited by
        inherited/acquired resistance, and biomarkers to adapt the prescription of
        anticancer drugs to patients' features are urgently warranted. Areas covered.
        In oncology, pharmacogenetics should provide the way to select patients who
        may benefit from a specific therapy that best match the individual and tumor
        genetic profile, thus allowing maximum activity and minimal toxicity. The
        present review summarizes the main findings on NSCLC pharmacogenetics, critically
        reappraising the most important studies on polymorphisms correlated with outcome
        of pemetrexed and EGFR-inhibitors, and provides perspective on clinical application
        of genomic tests for treatment decision-making. Expert Opinion. A major challenge
        in NSCLC is the identification of subgroups of diseases/patients that will
        truly benefit from specific treatments. Ideally, convenient and minimally
        invasive tests to decipher biomarkers of chemosensitivity/resistance and toxicity
        should be developed alongside novel anticancer treatments. Integration with
        the latest generation of whole-genome analyses and liquid biopsies as well
        as prospective validation in large cohorts of patients will overcome the limitations
        of the traditional pharmacogenetic approaches.</Abstract>\r\n    <AuthorList>Santarpia,Mariacarmela,|Rolfo,Christian,|Peters,G,J|Leon,Leticia,G|Giovannetti,Elisa,</AuthorList>\r\n
        \   <AuthorCount>5</AuthorCount>\r\n    <KeywordList>GENOME-WIDE ASSOCIATION|PLATINUM-BASED
        CHEMOTHERAPY|MESSENGER-RNA|GROWTH-FACTOR RECEPTOR|DINUCLEOTIDE REPEAT POLYMORPHISM|THYMIDYLATE
        SYNTHASE|INTRON 1|RANDOMIZED PHASE-II|TYROSINE KINASE INHIBITORS|PEMETREXED-BASED
        CHEMOTHERAPY|lung cancer|pemetrexed|EGFR inhibitors|methodological challenges|pharmacogenetic
        studies</KeywordList>\r\n    <DocumentTypeList>Review</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>99</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26761638</PMID>\r\n    <WoSItemID>000370753000002</WoSItemID>\r\n
        \   <PublicationSourceTitle>EXPERT OPINION ON DRUG METABOLISM &amp; TOXICOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>12</Volume>\r\n    <Issue>3</Issue>\r\n    <Pagination>307-317</Pagination>\r\n
        \   <PublicationDate>2016-03-03T00:00:00</PublicationDate>\r\n    <PublicationYear>2016</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Biochemistry
        &amp; Molecular Biology|Pharmacology &amp; Pharmacy</PublicationSubjectCategoryList>\r\n
        \   <ISSN>1742-5255</ISSN>\r\n    <DOI>10.1517/17425255.2016.1141894</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>10</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>TAYLOR
        &amp; FRANCIS LTD</CopyrightPublisher>\r\n    <CopyrightCity>ABINGDON</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.831,2014,ClosestToPublicationYear|2.831,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>138/289;BIOCHEMISTRY &amp; MOLECULAR BIOLOGY;2014;SC;ClosestToPublicationYear|94/254;PHARMACOLOGY
        &amp; PHARMACY;2014;SC;ClosestToPublicationYear|138/289;BIOCHEMISTRY &amp;
        MOLECULAR BIOLOGY;2014;SC;MostRecentYear|94/254;PHARMACOLOGY &amp; PHARMACY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>OXON</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>75182037</PublicationItemID>\r\n    <Title>The Utilization
        of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy.</Title>\r\n
        \   <Abstract>Lung cancer is ranked first worldwide as one of the main cancers
        in terms of prevalence and mortality rate. The development of effective treatment
        strategies against lung cancer is therefore of paramount importance. Traditionally,
        chemotherapy was employed in the treatment of various cancers. However, the
        non-specific nature of the actions of chemotherapeutic drugs and the potential
        for tumors to develop resistance to these drugs may render chemotherapy a
        less favorable option for cancer treatment. Immunotherapy provides an alternative
        strategy for this purpose. It involves the utilization of the immune system
        and the immune effector cells to elicit an immune response to the tumors,
        thereby eliminating them. Strategies include the administration of pro-inflammatory
        cytokines for immune stimulation, the removal of immunological checkpoints
        using monoclonal antibodies, and the use of cancer vaccines to enhance immunity
        against tumors. This article summarizes the above strategies, highlights the
        reasons why immunotherapy is superior to chemotherapy for the purpose of tumor
        removal, and reviews the recent clinical studies comparing the clinical outcomes
        of patients undergoing immunotherapy and chemotherapy. The article also describes
        advances in immunotherapeutic strategies for the treatment of lung cancer.
        </Abstract>\r\n    <AuthorList>Chan,Carmen,WH|Tsui,Stephen,KW|Law,Bernard,MH|So,Winnie,KW|Tang,Fiona,WK|Wong,Cho-Lee,</AuthorList>\r\n
        \   <AuthorCount>6</AuthorCount>\r\n    <KeywordList>chemotherapy|immune system|immunotherapy|lung
        cancer</KeywordList>\r\n    <DocumentTypeList>Journal Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>26927069</PMID>\r\n    <PublicationSourceTitle>International
        journal of molecular sciences</PublicationSourceTitle>\r\n    <Volume>17</Volume>\r\n
        \   <Issue>3</Issue>\r\n    <PublicationDate>2016-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2016</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>1422-0067</ISSN>\r\n    <DOI>10.3390/ijms17030286</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>11</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <PublicationImpactFactorList>2.862,2014,ClosestToPublicationYear|2.862,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>134/289;BIOCHEMISTRY &amp; MOLECULAR BIOLOGY;2014;SC;ClosestToPublicationYear|45/157;CHEMISTRY,
        MULTIDISCIPLINARY;2014;SC;ClosestToPublicationYear|134/289;BIOCHEMISTRY &amp;
        MOLECULAR BIOLOGY;2014;SC;MostRecentYear|45/157;CHEMISTRY, MULTIDISCIPLINARY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>SWITZERLAND</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>74993773</PublicationItemID>\r\n
        \   <Title>Lung cancer treatment is influenced by income, education, age and
        place of residence in a country with universal health coverage</Title>\r\n
        \   <Abstract>Selection of lung cancer treatment should be based on tumour
        characteristics, physiological reserves and preferences of the patient. Our
        aims were to identify and quantify other factors associated with treatment
        received. Lung cancer patient data from 2002 to 2011 were obtained from the
        national population-based Cancer Registry of Norway, Statistics Norway and
        the Norwegian Patient Register. Multivariable logistic regression examined
        whether year of diagnosis, age, sex, education, income, health trust, smoking
        status, extent of disease, histology and comorbidities were associated with
        choice of treatment; surgery or radical or palliative radiotherapy, within
        1 year of diagnosis. Among the 24,324 lung cancer patients identified, the
        resection rate remained constant while the proportion of radical radiotherapy
        administered increased from 8.6 to 14.1%. Older patients, those with lower
        household incomes and certain health trusts were less likely to receive any
        treatment. Lower education and the male gender were identified as negative
        predictors for receiving surgery. Smoking history was positively associated
        with both radical and palliative radiotherapy, while comorbidity and symptoms
        were independently associated with receiving surgery and palliative radiotherapy.
        Although Norway is a highly egalitarian country with a free, universal healthcare
        system, this study indicates that surgery and radical and palliative radiotherapy
        were under-used among the elderly, those with a lower socioeconomic status
        and those living in certain health trusts.</Abstract>\r\n    <AuthorList>Nilssen,Yngvar,|Strand,Trond-Eirik,|Fjellbirkeland,Lars,|Bartnes,Kristian,|Brustugun,Odd,Terje|O'Connell,Dianne,L|Yu,Xue,Qin|Moller,Bjorn,</AuthorList>\r\n
        \   <AuthorCount>8</AuthorCount>\r\n    <KeywordList>SWEDEN|INEQUALITIES|SURGERY|SURGICAL
        RESECTION|SURVIVAL|NORWAY|STAGE|RADIOTHERAPY|SOCIOECONOMIC POSITION|PALLIATIVE
        RADIATION-THERAPY|surgery|lung cancer|radiotherapy|national population-based</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>36</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26421593</PMID>\r\n    <WoSItemID>000370080900005</WoSItemID>\r\n
        \   <PublicationSourceTitle>INTERNATIONAL JOURNAL OF CANCER</PublicationSourceTitle>\r\n
        \   <Volume>138</Volume>\r\n    <Issue>6</Issue>\r\n    <Pagination>1350-1360</Pagination>\r\n
        \   <PublicationDate>2016-03-15T00:00:00</PublicationDate>\r\n    <PublicationYear>2016</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Oncology</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0020-7136</ISSN>\r\n    <DOI>10.1002/ijc.29875</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>12</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>WILEY-BLACKWELL</CopyrightPublisher>\r\n    <CopyrightCity>HOBOKEN</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>5.085,2014,ClosestToPublicationYear|5.085,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>31/211;ONCOLOGY;2014;SC;ClosestToPublicationYear|31/211;ONCOLOGY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NJ</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>74987116</PublicationItemID>\r\n    <Title>4D cone
        beam CT-based dose assessment for SBRT lung cancer treatment</Title>\r\n    <Abstract>The
        purpose of this research is to develop a 4DCBCT-based dose assessment method
        for calculating actual delivered dose for patients with significant respiratory
        motion or anatomical changes during the course of SBRT. To address the limitation
        of 4DCT-based dose assessment, we propose to calculate the delivered dose
        using time-varying ('fluoroscopic') 3D patient images generated from a 4DCBCT-based
        motion model. The method includes four steps: (1) before each treatment, 4DCBCT
        data is acquired with the patient in treatment position, based on which a
        patient-specific motion model is created using a principal components analysis
        algorithm. (2) During treatment, 2D time-varying kV projection images are
        continuously acquired, from which time-varying 'fluoroscopic' 3D images of
        the patient are reconstructed using the motion model. (3) Lateral truncation
        artifacts are corrected using planning 4DCT images. (4) The 3D dose distribution
        is computed for each timepoint in the set of 3D fluoroscopic images, from
        which the total effective 3D delivered dose is calculated by accumulating
        deformed dose distributions. This approach is validated using six modified
        XCAT phantoms with lung tumors and different respiratory motions derived from
        patient data. The estimated doses are compared to that calculated using ground-truth
        XCAT phantoms. For each XCAT phantom, the calculated delivered tumor dose
        values generally follow the same trend as that of the ground truth and at
        most timepoints the difference is less than 5%. For the overall delivered
        dose, the normalized error of calculated 3D dose distribution is generally
        less than 3% and the tumor D95 error is less than 1.5%. XCAT phantom studies
        indicate the potential of the proposed method to accurately estimate 3D tumor
        dose distributions for SBRT lung treatment based on 4DCBCT imaging and motion
        modeling. Further research is necessary to investigate its performance for
        clinical patient data.</Abstract>\r\n    <AuthorList>Cai,Weixing,|Dhou,Salam,|Cifter,Fulya,|Myronakis,Marios,|Hurwitz,Martina,H|Williams,Christopher,L|Berbeco,Ross,I|Seco,Joao,|Lewis,John,H</AuthorList>\r\n
        \   <AuthorCount>9</AuthorCount>\r\n    <KeywordList>IMAGE|FEASIBILITY|VERIFICATION|RESPIRATORY
        MOTION|MONTE-CARLO|STEREOTACTIC BODY RADIOTHERAPY|EPID DOSIMETRY|MOTION MODEL|3D
        TUMOR-LOCALIZATION|X-RAY PROJECTION|dose assessment|respiratory motion|SBRT|treatment
        verification|4D cone beam CT</KeywordList>\r\n    <DocumentTypeList>Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences>31</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26683530</PMID>\r\n    <WoSItemID>000369516600011</WoSItemID>\r\n
        \   <PublicationSourceTitle>PHYSICS IN MEDICINE AND BIOLOGY</PublicationSourceTitle>\r\n
        \   <Volume>61</Volume>\r\n    <Issue>2</Issue>\r\n    <Pagination>554-568</Pagination>\r\n
        \   <PublicationDate>2016-01-21T00:00:00</PublicationDate>\r\n    <PublicationYear>2016</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Engineering,
        Biomedical|Radiology, Nuclear Medicine &amp; Medical Imaging</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0031-9155</ISSN>\r\n    <DOI>10.1088/0031-9155/61/2/554</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>13</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>IOP PUBLISHING
        LTD</CopyrightPublisher>\r\n    <CopyrightCity>BRISTOL</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>2.761,2014,ClosestToPublicationYear|2.761,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>21/76;ENGINEERING, BIOMEDICAL;2014;SC;ClosestToPublicationYear|34/125;RADIOLOGY,
        NUCLEAR MEDICINE &amp; MEDICAL IMAGING;2014;SC;ClosestToPublicationYear|21/76;ENGINEERING,
        BIOMEDICAL;2014;SC;MostRecentYear|34/125;RADIOLOGY, NUCLEAR MEDICINE &amp;
        MEDICAL IMAGING;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0|8,0,0|9,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince />\r\n    <CopyrightCountry>UNITED KINGDOM</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>74927691</PublicationItemID>\r\n
        \   <Title>Lung cancer treatment outcomes in recipients of lung transplant.</Title>\r\n
        \   <Abstract>BACKGROUND Lung transplant recipients develop lung cancer more
        commonly than the general population. The best treatment approach for these
        patients is unclear. The goal of this study is to evaluate treatment outcomes
        in this population.\r\nMETHODS We used the Cleveland Clinic lung transplant
        database to identify patients diagnosed with lung cancer at the time of or
        after lung transplant. Transplant and lung cancer-related data were retrospectively
        reviewed.\r\nRESULTS Among 847 patients underwent lung transplant between
        2005 and 2013, 17 (2%) were diagnosed with lung cancer and included. Median
        age was 61 (range, 48-70) years. Majority were stage I/II (n=11), one had
        stage IIIA, five had stage IV. Non-small cell lung cancer (NSCLC) were more
        common than small cell lung cancer (SCLC) (n=15 vs. 2). Curative treatment
        was performed as lobectomy in native lung (n=1), and radiation in transplanted
        lung (n=2). Chemotherapy was given in 10 patients, primarily carboplatin-based
        doublets with docetaxel, pemetrexed, or etoposide. Six of these received palliative
        chemotherapy for either metastases at diagnosis (n=3) or recurrence after
        early stage disease (n=3). Except for one patient with complete response,
        all others had progressive disease following palliative chemotherapy. Overall,
        patients who received chemotherapy had a median survival of 7.5 months from
        the initiation of chemotherapy, but 30% developed grade 5 sepsis. Median survival
        for stage I-IIIA and stage IV were 23.2 and 2.5 months respectively.\r\nCONCLUSIONS
        Lung cancer in lung transplant recipients carries various clinical courses.
        Patients with metastatic disease have substantial toxicities from chemotherapy
        and poor survival. Early stage patients should be offered treatment with modified
        dosages to decrease the risk of severe toxicities.</Abstract>\r\n    <AuthorList>Du,Lingling,|Pennell,Nathan,A|Elson,Paul,|Hashemi-Sadraei,Nooshin,</AuthorList>\r\n
        \   <AuthorCount>4</AuthorCount>\r\n    <KeywordList>Lung cancer|chemotherapy|lung
        transplant|outcome</KeywordList>\r\n    <DocumentTypeList>Journal Article</DocumentTypeList>\r\n
        \   <DocumentCategory>Journal Document</DocumentCategory>\r\n    <NumberOfReferences
        xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\" />\r\n    <TimesNotSelfCited
        xsi:nil=\"true\" />\r\n    <PMID>26798588</PMID>\r\n    <PublicationSourceTitle>Translational
        lung cancer research</PublicationSourceTitle>\r\n    <Volume>4</Volume>\r\n
        \   <Issue>6</Issue>\r\n    <Pagination>784-791</Pagination>\r\n    <PublicationDate>2015-12-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationSubjectCategoryList
        />\r\n    <ISSN>2218-6751</ISSN>\r\n    <DOI>10.3978/j.issn.2218-6751.2015.12.08</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>14</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>CHINA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>74753108</PublicationItemID>\r\n
        \   <Title>TAREXTUMAB Anti-Notch 2/3 MAb Treatment of small cell lung cancer
        Treatment of pancreatic cancer</Title>\r\n    <Abstract>Notch (neurogenic
        locus notch homolog protein) signaling is a highly conserved pathway, with
        many roles at various stages during development. Interestingly, Notch is also
        a powerful stem cell-promoting pathway, which makes it a potential target
        for therapeutic strategies in many types of tumors due to the undifferentiated
        or de-differentiated state of cancer cells. Different approaches have been
        attempted to inhibit Notch signaling, including gamma-secretase inhibitors,
        alpha-secretase inhibitors and monoclonal antibodies targeting Notch family
        members. Of these antibodies against Notch, ligands such as delta-like protein
        4 have shown promising results as an antiangiogenic strategy. However, these
        have also been found to cause vascular or endothelial cell-based tumors after
        prolonged treatment in mice. Tarextumab (OMP-59R5) is a novel monoclonal antibody
        specifically targeting Notch 2/3, currently under active development by OncoMed
        Pharmaceuticals. Preclinical and clinical studies with this compound have
        shown promising results for this antibody, alone or in combination with standard
        chemotherapy, in various types of solid tumors including pancreatic cancer
        and small cell lung cancer. This is a review of the development of tarextumab,
        including main findings in both preclinical and clinical settings.</Abstract>\r\n
        \   <AuthorList>Marques,F,</AuthorList>\r\n    <AuthorCount>1</AuthorCount>\r\n
        \   <KeywordList>CELLS|INHIBITS TUMOR-GROWTH|SIGNALING PATHWAY|LUNG-CANCER|ANGIOGENESIS|EXPRESSION|DLL4|NUCLEAR
        NOTCH3|Notch signaling|pancreatic cancer|small cell lung cancer|OMP-59R5|Tarextumab</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>36</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000368416500002</WoSItemID>\r\n
        \   <PublicationSourceTitle>DRUGS OF THE FUTURE</PublicationSourceTitle>\r\n
        \   <Volume>40</Volume>\r\n    <Issue>12</Issue>\r\n    <Pagination>809-812</Pagination>\r\n
        \   <PublicationDate>2015-12-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationType>Journal</PublicationType>\r\n    <PublicationSubjectCategoryList>Pharmacology
        &amp; Pharmacy</PublicationSubjectCategoryList>\r\n    <ISSN>0377-8282</ISSN>\r\n
        \   <DOI>10.1358/dof.2015.040.12.2420732</DOI>\r\n    <ConferenceStartDate
        xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank
        xsi:nil=\"true\" />\r\n    <OrdinalRank>15</OrdinalRank>\r\n    <NormalizedRank
        xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>PROUS SCIENCE, SAU-THOMSON REUTERS</CopyrightPublisher>\r\n
        \   <CopyrightCity>BARCELONA</CopyrightCity>\r\n    <PublicationImpactFactorList>0.17,2014,ClosestToPublicationYear|0.17,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>253/254;PHARMACOLOGY &amp; PHARMACY;2014;SC;ClosestToPublicationYear|253/254;PHARMACOLOGY
        &amp; PHARMACY;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0</AuthorCitationCountList>\r\n    <CopyrightStateProvince
        />\r\n    <CopyrightCountry>SPAIN</CopyrightCountry>\r\n  </PublicationItem>\r\n
        \ <PublicationItem>\r\n    <PublicationItemID>73915356</PublicationItemID>\r\n
        \   <Title>WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL
        PUBLIC VALUES (vol 31, pg 264, 2015)</Title>\r\n    <Abstract>Owing to an
        editorial error, in the article by Thongprasert et al. (1) in the August 2015
        issue of International Journal of Technical Assessment in Health Care, Bruce
        Crawford was incorrectly listed as the corresponding author. The corresponding
        author is Unchalee Permsuwan.</Abstract>\r\n    <AuthorList>Thongprasert,Sumitra,|Crawford,Bruce,|Sakulbumrungsil,Rungpetch,|Chaiyakunapruk,Nathorn,|Petcharapiruch,Sirinthip,|Leartsakulpanitch,Jittrakul,|Permsuwan,Unchalee,</AuthorList>\r\n
        \   <AuthorCount>7</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Correction</DocumentTypeList>\r\n
        \   <DocumentCategory>Other</DocumentCategory>\r\n    <NumberOfReferences>1</NumberOfReferences>\r\n
        \   <TimesCited>0</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID xsi:nil=\"true\" />\r\n    <WoSItemID>000366655300015</WoSItemID>\r\n
        \   <PublicationSourceTitle>INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT
        IN HEALTH CARE</PublicationSourceTitle>\r\n    <Volume>31</Volume>\r\n    <Issue>4</Issue>\r\n
        \   <Pagination>271-271</Pagination>\r\n    <PublicationDate>2015-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Health Care Sciences &amp; Services|Public,
        Environmental &amp; Occupational Health|Medical Informatics</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0266-4623</ISSN>\r\n    <DOI>10.1017/S026646231500063X</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>16</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>CAMBRIDGE
        UNIV PRESS</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>1.308,2014,ClosestToPublicationYear|1.308,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>65/89;HEALTH CARE SCIENCES &amp; SERVICES;2014;SC;ClosestToPublicationYear|101/162;PUBLIC,
        ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH;2014;SC;ClosestToPublicationYear|18/24;MEDICAL
        INFORMATICS;2014;SC;ClosestToPublicationYear|65/89;HEALTH CARE SCIENCES &amp;
        SERVICES;2014;SC;MostRecentYear|101/162;PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL
        HEALTH;2014;SC;MostRecentYear|18/24;MEDICAL INFORMATICS;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,0,0|2,0,0|3,0,0|4,0,0|5,0,0|6,0,0|7,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>73861659</PublicationItemID>\r\n    <Title>China experts
        consensus on icotinib for non-small cell lung cancer treatment (2015 version).</Title>\r\n
        \   <Abstract />\r\n    <AuthorList>Shi,Yuankai,|Sun,Yan,|Ding,Cuimin,|Wang,Ziping,|Wang,Changli,|Wang,Zheng,|Bai,Chong,|Bai,Chunxue,|Feng,Jifeng,|Liu,Xiaoqing,|Li,Fang,|Yang,Yue,|Shu,Yongqian,|Wu,Milu,|He,Jianxing,|Zhang,Yiping,|Zhang,Shucai,|Chen,Gongyan,|Luo,Honghe,|Luo,Rongcheng,|Zhou,Caicun,|Zhou,Yanbin,|Pang,Qingsong,|Zhao,Hong,|Zhao,Qiong,|Gu,Aiqin,|Ling,Yang,|Huang,Cheng,|Han,Baohui,|Jiao,Shunchang,|Jiao,Hong,</AuthorList>\r\n
        \   <AuthorCount>31</AuthorCount>\r\n    <KeywordList />\r\n    <DocumentTypeList>Journal
        Article|Review</DocumentTypeList>\r\n    <DocumentCategory>Journal Document</DocumentCategory>\r\n
        \   <NumberOfReferences xsi:nil=\"true\" />\r\n    <TimesCited xsi:nil=\"true\"
        />\r\n    <TimesNotSelfCited xsi:nil=\"true\" />\r\n    <PMID>26605306</PMID>\r\n
        \   <PublicationSourceTitle>Annals of translational medicine</PublicationSourceTitle>\r\n
        \   <Volume>3</Volume>\r\n    <Issue>18</Issue>\r\n    <Pagination>260-?</Pagination>\r\n
        \   <PublicationDate>2015-10-01T00:00:00</PublicationDate>\r\n    <PublicationYear>2015</PublicationYear>\r\n
        \   <PublicationSubjectCategoryList />\r\n    <ISSN>2305-5839</ISSN>\r\n    <DOI>10.3978/j.issn.2305-5839.2015.10.30</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>17</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher />\r\n
        \   <CopyrightCity />\r\n    <CopyrightStateProvince />\r\n    <CopyrightCountry>CHINA</CopyrightCountry>\r\n
        \ </PublicationItem>\r\n  <PublicationItem>\r\n    <PublicationItemID>73856784</PublicationItemID>\r\n
        \   <Title>WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL
        PUBLIC VALUES</Title>\r\n    <Abstract>Objectives: Lung cancer has been the
        most common cancer since 1985, accounting for 12-13 percent of cancer cases
        worldwide. Newer targeted therapies with potential increased survival benefits
        may not be affordable to patients. Many countries use arbitrary thresholds
        to determine whether a medical intervention is cost-effective. As such, many
        effective, albeit expensive, therapies are not being reimbursed. To understand
        the value placed on effective therapies, this study evaluates the patient
        and public willingness to pay (WTP) for a quality-adjusted life-year (QALY)
        for lung cancer treatments using Thailand as an example.  Methods: A total
        of 300 subjects responded to hypothetical lung cancer health states, described
        by three levels of severity and two levels of side effects, and provided their
        valuation of the level of quality of life and their WTP to improve from one
        state to another.  Results: The patients with the lowest income and general
        public were willing to pay more than twice the threshold for acceptability
        in Thailand (US Dollar 5,123/QALY [Thai Baht 160,000/QALY]). This increased
        significantly by wealth category. Patients' WTP was associated with quality
        of life, financial difficulties, health insurance, diarrhea, and wealth.  Conclusions:
        The current study highlights the value patients and general public place on
        effective lung cancer therapies.</Abstract>\r\n    <AuthorList>Thongprasert,Sumitra,|Crawford,Bruce,|Sakulbumrungsil,Rungpetch,|Chaiyakunapruk,Nathorn,|Petcharapiruch,Sirinthip,|Leartsakulpanitch,Jittrakul,|Permsuwan,Unchalee,</AuthorList>\r\n
        \   <AuthorCount>7</AuthorCount>\r\n    <KeywordList>willingness-to-pay|lung
        cancer|health economics|cancer treatment|pharmacoeconomics</KeywordList>\r\n
        \   <DocumentTypeList>Article</DocumentTypeList>\r\n    <DocumentCategory>Journal
        Document</DocumentCategory>\r\n    <NumberOfReferences>13</NumberOfReferences>\r\n
        \   <TimesCited>1</TimesCited>\r\n    <TimesNotSelfCited>0</TimesNotSelfCited>\r\n
        \   <PMID>26353902</PMID>\r\n    <WoSItemID>000366655300014</WoSItemID>\r\n
        \   <PublicationSourceTitle>INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT
        IN HEALTH CARE</PublicationSourceTitle>\r\n    <Volume>31</Volume>\r\n    <Issue>4</Issue>\r\n
        \   <Pagination>264-270</Pagination>\r\n    <PublicationDate>2015-01-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Health Care Sciences &amp; Services|Public,
        Environmental &amp; Occupational Health|Medical Informatics</PublicationSubjectCategoryList>\r\n
        \   <ISSN>0266-4623</ISSN>\r\n    <DOI>10.1017/S0266462315000409</DOI>\r\n
        \   <ConferenceStartDate xsi:nil=\"true\" />\r\n    <ConferenceEndDate xsi:nil=\"true\"
        />\r\n    <Rank xsi:nil=\"true\" />\r\n    <OrdinalRank>18</OrdinalRank>\r\n
        \   <NormalizedRank xsi:nil=\"true\" />\r\n    <NewPublicationItemID xsi:nil=\"true\"
        />\r\n    <IsObsolete>false</IsObsolete>\r\n    <CopyrightPublisher>CAMBRIDGE
        UNIV PRESS</CopyrightPublisher>\r\n    <CopyrightCity>NEW YORK</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>1.308,2014,ClosestToPublicationYear|1.308,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>65/89;HEALTH CARE SCIENCES &amp; SERVICES;2014;SC;ClosestToPublicationYear|101/162;PUBLIC,
        ENVIRONMENTAL &amp; OCCUPATIONAL HEALTH;2014;SC;ClosestToPublicationYear|18/24;MEDICAL
        INFORMATICS;2014;SC;ClosestToPublicationYear|65/89;HEALTH CARE SCIENCES &amp;
        SERVICES;2014;SC;MostRecentYear|101/162;PUBLIC, ENVIRONMENTAL &amp; OCCUPATIONAL
        HEALTH;2014;SC;MostRecentYear|18/24;MEDICAL INFORMATICS;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n
        \   <AuthorCitationCountList>1,1,0|2,1,0|3,1,0|4,1,0|5,1,0|6,1,0|7,1,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>NY</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        STATES</CopyrightCountry>\r\n  </PublicationItem>\r\n  <PublicationItem>\r\n
        \   <PublicationItemID>73843960</PublicationItemID>\r\n    <Title>Immunotherapy:
        the third wave in lung cancer treatment</Title>\r\n    <Abstract />\r\n    <AuthorList>Heigener,David,Felix|Reck,Martin,</AuthorList>\r\n
        \   <AuthorCount>2</AuthorCount>\r\n    <KeywordList>DOCETAXEL|NIVOLUMAB|BMS-936558|ONO-4538</KeywordList>\r\n
        \   <DocumentTypeList>Editorial Material</DocumentTypeList>\r\n    <DocumentCategory>Other</DocumentCategory>\r\n
        \   <NumberOfReferences>7</NumberOfReferences>\r\n    <TimesCited>0</TimesCited>\r\n
        \   <TimesNotSelfCited>0</TimesNotSelfCited>\r\n    <PMID>26679022</PMID>\r\n
        \   <WoSItemID>000365817900023</WoSItemID>\r\n    <PublicationSourceTitle>LANCET
        RESPIRATORY MEDICINE</PublicationSourceTitle>\r\n    <Volume>3</Volume>\r\n
        \   <Issue>12</Issue>\r\n    <Pagination>923-924</Pagination>\r\n    <PublicationDate>2015-12-01T00:00:00</PublicationDate>\r\n
        \   <PublicationYear>2015</PublicationYear>\r\n    <PublicationType>Journal</PublicationType>\r\n
        \   <PublicationSubjectCategoryList>Critical Care Medicine|Respiratory System</PublicationSubjectCategoryList>\r\n
        \   <ISSN>2213-2600</ISSN>\r\n    <ConferenceStartDate xsi:nil=\"true\" />\r\n
        \   <ConferenceEndDate xsi:nil=\"true\" />\r\n    <Rank xsi:nil=\"true\" />\r\n
        \   <OrdinalRank>19</OrdinalRank>\r\n    <NormalizedRank xsi:nil=\"true\"
        />\r\n    <NewPublicationItemID xsi:nil=\"true\" />\r\n    <IsObsolete>false</IsObsolete>\r\n
        \   <CopyrightPublisher>ELSEVIER SCI LTD</CopyrightPublisher>\r\n    <CopyrightCity>OXFORD</CopyrightCity>\r\n
        \   <PublicationImpactFactorList>9.629,2014,ClosestToPublicationYear|9.629,2014,MostRecentYear</PublicationImpactFactorList>\r\n
        \   <PublicationCategoryRankingList>2/57;RESPIRATORY SYSTEM;2014;SC;ClosestToPublicationYear|2/57;RESPIRATORY
        SYSTEM;2014;SC;MostRecentYear</PublicationCategoryRankingList>\r\n    <AuthorCitationCountList>1,0,0|2,0,0</AuthorCitationCountList>\r\n
        \   <CopyrightStateProvince>OXON</CopyrightStateProvince>\r\n    <CopyrightCountry>UNITED
        KINGDOM</CopyrightCountry>\r\n  </PublicationItem>\r\n</ArrayOfPublicationItem>"
    http_version: 
  recorded_at: Wed, 04 May 2016 00:38:37 GMT
recorded_with: VCR 3.0.1
